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Abstract 
 
In the present investigation peripheral blood lymphocytes from patients with 
inflammatory bowel disease (IBD) and different cancer states were treated with various 
agents and compared with lymphocytes from healthy control individuals (HCI) treated in 
the same way and measured in the Comet assay. For inflammatory bowel disease, 
patient’s responses in IBD patients treated with H2O2 were higher than in HCI and 
crohn’s patients (CD) were found to have higher responses than Ulcerative colitis (UC) 
patients. The responses for all IBD and HCI were all reduced in the presence of chaga 
mushroom extract which behaved in an antioxidant manner. A second group of IBD 
patients were treated with the heterocyclic amine (food mutagen), IQ and H2O2 and 
responses were reduced in the presence of the flavonoids, quercetin and epicatechin and 
compared with HCI similarity treated. In all cells responses were reduced with 
flavonoids and again CD had higher responses than the UC patients and IBD patients 
higher than HCI. The responses with CD and UC were that confirmed in two 
independent studies with IBD, one with chaga mushroom extract and the other with 
flavonoids. 
Peripheral lymphocytes from malignant melanoma and suspected melanoma patients and 
colon cancer and polyposis patients were compared to the lymphocytes from HCI and 
treated with UVA. There were differential sensitivities when measured in the 
micronucleus and Comet assays. The cancer patients had higher responses than those in 
the precancerous states and they in turn were higher than responses in HCI. In all the 
studies, untreated baseline DNA damage values were also higher in IBD and cancer 
patients and pre-cancerous patients than HCIs. This would suggest that baseline 
frequencies of different diseases compared to controls could be an important biomarker 
in the diagnosis of pre-cancers and early stage cancers. Also peripheral lymphocytes are 
a useful surrogate for cancers and pre-cancerous disease states since, blood is present in 
all organs and tissues and DNA is basically the same in all cells. 
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1.0. Introduction 
 
1.1. Inflammatory Bowel disease 
 
Inflammatory bowel disease (IBD) covers a group of disorders that cause 
inflammation of the intestine and consists of both Crohn’s disease (CD) and 
Ulcerative colitis (UC) ((author,year)Rhodes, Thomas et al. 1997). These 
disorders have distinct pathologic and clinical characteristics but their 
pathogenesis remains poorly understood. Infectious gastroenteritis (IGE) is 
known to exacerbate previously diagnosed inflammatory bowel disease IBD. The 
initiation of IBD is a multifactorial process that might include the disruption of 
normal gut homeostatic mechanisms. More studies are warranted to evaluate the 
pathogen-specific risks, identify susceptible populations, and better understand 
the pathophysiologic relationship between IGE and IBD (Porter, 2008). 
Environmental factors play an important role in the pathophysiology of IBD. 
There is a strong and consistent association between smoking and Crohn's 
disease, and between non-smoking and Ulcerative colitis. Despite extensive 
research, the exact pathophysiological mechanisms for these associations remain 
unclear. In spite of this, some clinical trials with nicotine-patches showed 
beneficial effects for the treatment of Ulcerative colitis. Associations of Crohn's 
disease and Ulcerative colitis with other environmental factors are weaker like 
the association with use of oral contraceptives or those less well investigated 
such as the association with childhood hygiene. Most studies suggesting a 
potential pathogenetic role of Mycobacterium paratuberculosis or an effect of 
tuberculostatic therapy in Crohn's disease could not be reproduced by others 
 30 
(Andus, 2000). Perinatal or childhood infections by viruses like measles are 
heavily debated, but not proven to be causal for IBD. Coagulation disorders have 
been described as protecting from inflammatory bowel disease, suggesting 
hypercoagulability to be a pathogenetic factor (Andus, 2000). Some studies 
described that appendectomy may prevent the onset of Ulcerative colitis in man 
and mice. Other environmental factors such as hydrogen sulphide, tonsillectomy, 
diet, blood transfusions, and Listeria also require confirmation (Andus, 2000). 
There are, however, convincing data from genetic animal models and twin 
studies that environmental factors such as the intestinal bacterial flora interact 
with susceptible hosts to cause inflammatory bowel disease. Inflammatory bowel 
diseases have multifactorial aetiologies, which require a differentiated approach 
for treatment and prevention (Andus, 2000). 
 
1.1.1.1. Signs and Symptoms of Crohn’s disease 
In contrast to Ulcerative colitis, Crohn's disease is characterized by transmural 
rather than superficial mucosal inflammation and by skip lesions rather than 
continuous disease. The transmural inflammatory nature of Crohn's disease often 
leads to fibrosis and to obstructive clinical presentations which are not typically 
seen in Ulcerative colitis. The transmural inflammation can also result in sinus 
tracts that burrow through and penetrate the serosa, giving rise to 
microperforations and fistulae. Crohn's disease may involve the entire 
gastrointestinal tract from mouth to perianal area (Nigg, 2008). 
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1.1.1. 2. Distribution of Crohn's disease  
 
The studies have shown that both Crohn's disease and Ulcerative colitis affect 
people in white collar occupations associated with higher income and higher 
social class more frequently than other groups in the population (Sonnenberg, 
1990). 
These associations were found in the complete data for 1982-8 as well as in the 
separate data for the two half periods 1982-5 and 1986-8. Highly significant 
correlations between the occupational distribution of Crohn's disease and 
Ulcerative colitis were found among both male and female employees. It seems 
that occupations involving work in the open air and physical exercise are 
protective, while being exposed to air conditioned artificial working conditions 
or extended and irregular shift working confer a risk of contracting inflammatory 
bowel disease (Sonnenberg, 1990). 
 
 
Figure 1.1. Approximate frequency of ileal and colonic involvement in Crohn's disease. Crohn's disease 
can involve the entire gastrointestinal tract from mouth to perianal area. Courtesy of the American 
Gastroenterological Association©.  
 
 32 
 
1.1.1.3. Signs and Symptoms of Ulcerative colitis 
 
Ulcerative colitis is characterized by recurring episodes of inflammation limited 
to the mucosal layer of the colon. It almost invariably involves the rectum and 
may extend in a proximal and continuous fashion to involve other portions of the 
colon. Different terms are used to describe the degree of involvement. Ulcerative 
proctitis refers to disease limited to the rectum (Farrell, 2002 ;Farrell, 2002). 
Patients with Ulcerative colitis can have a variable presentation. For therapeutic 
and prognostic purposes, it has been useful to classify these presentations as mild, 
moderate, and severe. The severity of the symptomatology often correlates with 
the anatomic extent of the disease, another parameter that will guide therapy. 
 
 
1.1.1.3.1. Mild disease  
Patients whose disease is confined to the rectum (proctitis) or rectosigmoid 
(proctosigmoiditis or distal colitis), often present insidiously with intermittent 
rectal bleeding associated with the passage of mucus, and the development of 
mild diarrhoea with fewer than four small loose stools per day. Mild crampy pain, 
tenesmus, and periods of constipation are also common, but severe abdominal 
pain, profuse bleeding, fever, and weight loss are not part of the spectrum of mild 
disease. 
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1.1.1.3.2. Moderate disease  
 
Moderate disease is usually characterized anatomically by involvement of more 
than the distal colon, with the inflammatory process extending to at least the 
splenic flexure (left-sided colitis). The clinical picture is characterized by 
frequent loose, bloody stools (up to 10 per day), mild anaemia not requiring 
blood transfusions, abdominal pain that is not severe, and low grade fever. 
Adequate nutrition is usually maintained. Approximately 80 percent of patients 
have small bowel involvement, usually in the distal ileum, with one-third of 
patients having exclusively ileitis (Gitnick, 1994). 
Approximately 50 percent of patients have ileocolitis which refers to 
involvement of both the ileum and colon. Approximately 20 percent have disease 
limited to the colon (Lewis, 2004). Although this pattern is similar to that in 
Ulcerative colitis, roughly one-half of such patients have sparing of the rectum 
which is rare in Ulcerative colitis. 
 
1.1.1.3.3. Severe disease 
 Severe Ulcerative colitis, the least common form of the disease, occurs in 15% 
of all patients with Ulcerative colitis. This form of the disease may be the initial 
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presentation or may represent a progression from a less severe attack. Diarrhoea 
is profuse and rectal bleeding is constant and severe. Fever is marked and 
sustained, and appetite and weight are both severely diminished. Abdominal 
cramps are severe and tenderness may be localized, indicating impending 
perforation. Leukocytes greater than 10,000, severe anaemia, and 
hypoalbuminemia resulting from low protein intake (anorexia) and increased 
chronic loss of albumin are hallmarks of this form of the disease 
Medical therapy is often ineffective for this type of patient, and colonectomy is 
often required (Thompson, 1997). 
 A small percentage has a predominant involvement of the mouth or 
gastroduodenal area, while fewer patients have involvement of the oesophagus 
and proximal small bowel. Approximately one-third of patients have perianal 
disease. Its precise aetiology remains unknown, but it is a multifactorial disorder 
involving genetic, environmental, microbial and immune factors (Fiocchi, 2005). 
IBDs are thought to result from unchallenged immune responses to normal flora 
in genetically susceptible hosts.  The condition known as IBD has only been 
identified for 70 years and seems to be on the increase in developed countries 
within North America and Europe and Scandinavia. Crohn’s disease was first 
described in 1932 and may affect any part of the gastrointestinal tract.  
Ulcerative colitis is a chronic relapsing inflammatory disorder affecting the 
colonic and rectal mucosa. For the different disease states, although quite distinct 
pathologically, the treatment including drug therapy is often very similar. 
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TABLE 1.1. 1.  Clinical differentiation of Ulcerative colitis from Crohn's colitis  
 
Feature Ulcerative colitis Crohn's colitis 
 
Clinical features   
Rectal bleeding Very common - 90% Uncommon: may be occult 
Diarrhoea Early, frequent, small stools Less prevalent or absent 
Abdominal pain Predefecatory, urgency Colicky, postprandial 
Fever Uncommon if 
uncomplicated 
Frequent 
Palpable mass Rare Frequent, right lower quadrant 
Recurrence after resection Rare Frequent 
Clinical course Relapses/remissions 65% 
Chronic/continuous 20-
30%   
Acute/fulminating 5-8% 
Usually slowly progressive; 
fulminant 
Endoscopical  features   
Proctosigmoidoscopy Diffuse pinpoint 
ulcerations,continuous 
lesions 
Discrete aphthoid ulcerations, patchy 
lesions 
Radiological  features   
Rectal involvement Invariable Infrequent 
Distribution Continuous Segmental, discontinuous 
Mucosa Fine ulcerations "Cobblestones" 
Strictures Rare Frequent 
Fistulas Rare Frequent 
Histological  features   
Distribution Mucosal Transmural 
Cellular infiltrate Polymorphs Lymphocytes 
Glands Mucin depletion 
 Gland destruction 
 Crypt abscesses  
Gland preservation 
Special features None Granulomas, aphthoid ulcers, 
histiocyte-lined fissures 
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Adapted From: First Principles of Gastroenterology: The Basis of Disease and an Approach to 
Management, 1997. 
 
The most likely age of onset of IBD is bimodal and lies between 15-30 years or 
60-80 years. The male to female ratio for UC is 1/1 and for CD is 1.8/ 1 (Kirsner, 
1991). Inflammatory bowel diseases are a public health problem in industrialized 
countries, where 1 in 1000 people is affected. Most patients are young adults. 
The incidence of IBD has increased considerably in western countries since the 
Second World War but is beginning to level off. On the other hand, the incidence 
is still rising in low-incidence areas such as Eastern Europe, Asia and developing 
countries (Gismera, 2001; Guariso, 2010). One of the important factors in the 
immunopathogenesis of IBD is diet and  basically it acts as luminal antigens, but 
whether antibodies against dietary antigens play a primary role in IBD aetiology 
or are secondary to intestinal inflammation is yet to be established (Yamamoto, 
2009). Differences in incidence rates across age, time, and geographic areas 
suggest that environmental factors are involved in IBD, but only cigarette 
smoking and appendectomy have consistently been identified as risk factors. An 
important role of genetic factors in IBD was first suggested by epidemiological 
studies showing familial aggregation of IBD and by twin studies. Numerous 
studies from Europe and North America have provided a wealth of information 
regarding the epidemiological and clinical characteristics of IBD in Caucasians 
(Gismera, 2001). Previous studies in mainland China have been limited by small 
patient numbers or by lack of detailed information about clinical subgroups of 
the disease. This limited study was carried out to assess the demographic and 
clinical characteristics of IBD in Chinese patients. In the Sir Run Shaw Hospital 
between 1994 and 2003, 379 patients were diagnosed with IBD. Demographic 
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and clinical data were collected and analysed. Results: Of the 379 patients 
examined , 317 had Ulcerative colitis UC (83.6%, 168 male, 149 female, male-
female ratio, 1.13/1, age range at diagnosis 14-79 years, mean age 44 years) and 
62 had Crohn's disease CD (16.4%, 39 male and 23 female, male-female ratio 
1.70/1, age range at diagnosis 13-70 years, mean age 33 year (Cao, 2005 ;Ullman, 
2010). 
Seasonal variation in flares of IBD (with peaks in the spring) have been 
suggested in some reports, however the magnitude of the association, if any, is 
weak, and discordant data have also been published (Lewis, 2004).  
 
 
TABLE 1.1.2.   Endoscopic grading of activities in Ulcerative colitis  
 
Activity Appearance 
 
Quiescent Distorted or absent mucosal vascular 
pattern 
Granularity 
Mildly active Continuous or focal erythema 
Friability (touch bleeding) 
Moderately active Mucopurulent exudate (mucopus) 
Single or multiple ulcers (<5 mm); fewer 
than 10 per 10 cm segment 
Severe Large ulcers (>5 mm); more than 10 per 10 
cm segment 
Spontaneous bleeding 
 
Adapted from: First Principles of Gastroenterology: The Basis of Disease and an Approach to 
Management, 1997. 
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1.1.1.4. Epidemiology of inflammatory bowel disease  
 
TABLE1.1.3. Epidemiology of inflammatory bowel disease  
Incidence, per 100,000      3-14 (CD) 
(North America)               2-14 (UC) 
 
Incidence, per 100,000     26-199 (CD)  
(North America)                27-246 (UC) 
Geography                        Northern Countries > Southern Countries 
 
Age of onset                    Peak: 15-30 
                                        Second peak: 50-80 (CD) 
Sex                               M=F 
Race                            White > Blacks 
Ethnic                          Jewish > Non-Jewish 
Smoking                      Associated with CD: protective in UC 
Appendectomy            Maybe protective in UC 
Possible – genetic associations’ chromosome  
                                    Chromosome 16 (CD) 
                                     Chromosome 3,5,7,12,19 (UC and CD), TNF-(CD); IL-1A (CD), IL-23 receptor 
 
 
 
Adopted from:   First Principles of Gastroenterology: The Basis of Disease and an Approach 
to Management, 1997. 
  
 
 
 
 
  
  
 
 
 
In Ulcerative colitis, 11.4% of patients had proctitis, 25.2% had 
proctosigmoiditis, 18.6% were diseased to the splenic flexure and 44.8% had 
extensive colitis. Nine patients with UC (2.8%) had arthritis; three patients (0.9%) 
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had iritis or conjunctivitis. Of the 62 CD patients, 16 (25.8%) had diseases 
restricted to the terminal ileum; 15 (24.2%) had colonic diseases; 20 (32.3%) had 
ileocolonic disease and 11 (17.7%) had disease involving the upper 
gastrointestinal tract. This study showed similar characteristics of IBD to that in 
the West but there are some differences with respect to severity and 
extraintestinal manifestations. The ethnic and geographic differences may give 
important clues to the aetiology of IBD (Gismera, 2001).  
 
TABLE 1.1.4. Incidence and prevalence* of IBD from selected registries 
Location Year Incidence                    Prevalence* 
Crohn's disease 
Rochester, New York 1943-1982 4.3 90.5 
Malmo, Sweden 1958-1973 4.8 75.2 
Copenhagen, Denmark 1958-1978 1.8 34.0 
Tel Aviv, Israel 1970-1976 1.3 12.3 
North Tees, England 1971-1977 5.3 35.0 
Ulcerative colitis 
Rochester, New York 1960-1979 15.0 212.6 
Malmo, Sweden 1958-1973 6.4 89.0 
Copenhagen, Denmark 1962-1978 8.1 117.0 
Tel Aviv, Israel 1961-1970 3.7 37.4 
North Tees, England 1971-1977 15.1 99.0 
 
*Per100,00population 
 
IBD may cause a delay in puberty or growth problems because it can interfere 
with nutrition. Patients usually need extensive therapeutic treatment as a result of 
the chronic relapsing nature of the disease. Ten percent of patients have a first 
degree relative with the disease while siblings are affected 30 times more often 
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than the general population suggesting that genetic factors help susceptibility to 
IBD (Ueda, 1992).  
 
 
1.1.1.5. Diagnosis 
 
The diagnosis of inflammatory bowel disease can pose a significant challenge to 
gastroenterologists, mainly due to a wide array of clinical presentations that are 
related to the involvement of different portions of the gastrointestinal tract 
(Kirsner, 1991). Due to an absence of uniformity in clinical presentation and a 
lack of a single gold standard test, an accurate diagnosis and appropriate 
classification of IBD can often be challenging. Diagnosing small bowel (SB) 
involvement has been particularly challenging in the past due to a lack of 
adequate endoscopic and radiologic modalities to evaluate the entire SB. 
Endoscopy remains the cornerstone in the evaluation of IBD, with the diagnosis 
usually established by a combination of clinical symptoms, laboratory markers 
e.g. perinuclear antineutrophil cytoplasmic antibodies (pANCA), autoantibodies 
to intestinal goblet cells (GAB) and autoantibodies to exocrine pancreas (PAB) 
and endoscopic and radiologic features. One of the new methods to diagnose this 
disease is capsule endoscopy (Pasha, 2007; Homsak, 2010).  
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Adapted from:  First Principles of Gastroenterology: The Basis of Disease and an 
Approach to Management, 1997. 
 
 
 
 
 
  
Photograph 1.1.1. Pseudomembranous colitis appears as a tan to yellow-green exudate over an 
erythematous bowel mucosa. www.mda-sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
 
 
TABLE1.1.5.  Inflammatory bowel disease: indications for colonoscopy  
 
Differentiating IBD from other diseases and differentiating Crohn's from Ulcerative 
colitis 
Establishing the extent of the disease 
Screening for malignancy and malignant precursors 
Evaluation of abnormalities on radiographs  
 Strictures 
 Masses 
Evaluation of patients not responsive to standard therapy or examination to explain 
recent flare; searching for complications 
Examination prior to surgery  
 Detection of intestinal involvement (active IBD) in fistulous disease 
 Differentiation of Ulcerative colitis from Crohn's colitis 
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Photograph 1.1.2. Ulcerative colitis is seen here grossly in a total colectomy. There is diffuse 
involvement of the mucosa from the rectum proximally to the ascending colon. The caecum is 
not so 
 Severely involved, and the terminal ileum is not involved.  
www.mda-sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
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Photograph 1.1.3. Colonic adenocarcinoma is a long term risk with Ulcerative colitis. A large 
mass is seen extending into the lumen of the colon here. www.mda-
sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
 
  
 
Photograph 1.1.4. Crohn's disease is seen in this segmental resection of terminal ileum to involve the centre 
portion where the small intestinal wall is thickened and the mucosa is inflamed and ulcerated. 
www.mda-sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
Crohn's disease is a chronic, transmural, granulomatous disorder that can involve 
any segment of gastrointestinal tract from the mouth to the anus. In the bowel it 
may affect multiple distinct segments, with normal intervening bowel. Crohn's 
disease also may be complicated by intestinal strictures, fistulas, and perianal 
fistulas. The clinical presentation of Crohn's disease depends on the area of 
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gastrointestinal tract involved and ranges from intestinal obstruction, to bloody 
or non-bloody diarrhoea, to malabsorption (Kirsner, 1991; Huprich, 2010).  
Ulcerative colitis is a nongranulomatous inflammatory condition that always 
starts in the rectum and extends proximally throughout the colon in a continuous 
and confluent fashion, never involving the small bowel. The clinical presentation 
of Ulcerative colitis is more uniform than that of Crohn's disease and includes 
rectal bleeding or bloody diarrhoea. In addition to gastrointestinal symptoms, 
extraintestinal manifestations can occur and may involve the skin (e.g., erythema 
nodosum, pyoderma gangrenosum), joints (sacroiliitis, ankylosing spondylitis, 
and peripheral arthritis), eyes (iritis and uveitis), and liver (sclerosing 
cholangitis). Extraintestinal manifestations are more common with colonic than 
with small-bowel disease and are believed to be due to the release of bacterial 
antigens from the colonic lumen (Farrell, 2002 ;Mader, 2005).  
 
Photograph 1.1.5. Ulcerative colitis is seen grossly in the colon at higher magnification with the typical 
pattern of "pseudopolyps" from severe inflammation and mucosal erosion. The pseudopolyps are remaining 
islands of mucosa after the bulk of the mucosa has ulcerated away. www.mda-
sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
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The differential diagnostic considerations in IBD are wide and varied. In patients 
with new-onset bloody diarrhoea and abdominal cramps, an infectious cause 
must first be ruled out. In addition to routine cultures, cultures for Clostridium 
difficile, ova and parasites, and haemorrhagic Escherichia coli should be done. 
Colonic ischemia presents with symptoms similar to those of IBD--abdominal 
cramps, rectal bleeding, and diarrhoea--and should be a consideration in older 
patients. Nonsteroidal anti-inflammatory drugs can also cause colonic ulcerations 
that mimic colonic Crohn's disease (Farrell, 2002 ;Hussain, 2010).  
 
 
Figure 1.1.2. Inflammatory bowel disease subsets (Bayless, 2008). 
UC and CD have similar features to many other diseases. In the absence of a key 
diagnostic test, a combination of features is used. Once a diagnosis of IBD is 
made, distinguishing between UC and CD is impossible in up to 15% of cases. 
These are termed indeterminate colitis (Guindi, 2004; Tertychnyi, 2010). 
 Ulcerative colitis usually begins in the rectosigmoid and extends proximally; 
however, there is a subtype that is milder in degree which is limited to the rectum 
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(Ulcerative proctitis). In young patients, the entire colon is more often involved 
than in adults (Farrell, 2002) (Photograph 1.1.5). 
1.1.1.6. Pathology 
In Ulcerative colitis the characteristic
 
histological findings are acute and chronic 
inflammation of the
 
mucosa by polymorphonuclear leukocytes and mononuclear 
cells,
 
crypt abscesses, distortion of the mucosal glands, and goblet
 
cell depletion. 
Crohn’s disease, in contrast to UC, can involve any part of the gastrointestinal 
tract from the oropharynx to the perianal area (see later Photographs 1.1.9, 1.1.10, 
1.1.11). Diseased segments
 
frequently are separated by intervening normal bowel, 
leading
 
to the term "skip areas." Inflammation can be transmural, often
 
extending 
through to the serosa, resulting in sinus tracts or
 
fistula formation. Histological 
findings include small superficial
 ulcerations over a Peyer’s patch (aphthoid ulcer) 
and
 
focal chronic inflammation extending to the submucosa, sometimes
 
accompanied by noncaseating granuloma formation. The
 
most common location 
is the ileocecal region, followed by the
 
terminal ileum alone, diffuse small bowel, 
or isolated colonic
 
disease in decreasing order of frequency (Andus, 
2000 ;Asquith, 2010). 
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Photograph 1.1.6. Ulcerative colitis is shown microscopically at low power magnification to reveal mucosal 
inflammation and erosion. www.mda-sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
 
 
Photograph 1.1.7. Ulcerative colitis seen here microscopically at high power magnification demonstrates the 
presence of acute inflammatory cells within crypts, the so-called "crypt abscesses".www.mda-
sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
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Photograph 1.1.8. Ulcerative colitis in other areas may demonstrate crypt distortion and dysplasia, as seen 
here on the right microscopically. www.mda-sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
In Ulcerative colitis the pathological change begins with degeneration of the 
mucosal epithelium (specifically the reticulin fibres), occlusion of the 
subepithelial capillaries, and progressive infiltration of the lamina propria with 
white blood cells; all types invade but there is a predominance of PMN's 
(polymorphonuclear). Eventually, crypt abscesses, epithelial necrosis, and 
mucosal ulcerations develop (Bousvaros, 2007) (see later Photographs 1.1.6, 
1.1.7, 1.1.8). 
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Photograph 1.1.9. Crohn's disease microscopically at low power magnification can be seen to 
involve the full thickness of the wall from the mucosa to the serosa. Granulomas are seen toward 
the serosal surface here. www.mda-sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
 
Photograph 1.1.10. Crohn's disease microscopically at high power magnification may demonstrate 
granuloma formation. Special stains for infectious organisms will be negative. 
www.mda-sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
 
Photograph 1.1.11. Crohn's disease microscopically at medium power magnification is shown with a deep 
fissure extending through mucosa to the submucosa. This can result in fistula and/or abscess formation. 
www.mda-sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
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Photograph 1.1.12. Pseudomembranous colitis microscopically is seen as an adherent membrane of 
inflammatory cells and necrotic debris overlying the mucosa. www.mda-
sy.com/pathology/TUTORIAL/IBD/IBD011.HTM 
 
1.1.2. Oxidative stress and IBD 
 
Overproduction of colonic oxidants contributes to mucosal injury in 
inflammatory bowel disease (IBD) but the mechanisms are unclear. The findings 
using monolayers of intestinal cells suggest that the mechanism could be oxidant 
induced-damage to cytoskeletal proteins. However, oxidants and oxidative 
damage have not been well characterised in IBD mucosa (Keshavarzian, 2003).  
It has been shown in experimental animals as well as in humans that free radicals 
are released during inflammatory colitis (Loguercio, 1996; O'Connor, 2010). 
Hydrogen peroxide and reactive oxygen metabolites are generated in greater 
amounts in the inflamed bowel; the non-enzymatic pathway may be an additional 
route for nitric oxide radical (NO
•
) production in UC (Simmonds, 1993; Amini-
Shirazi, 2009). Whilst IBD is associated with free radical damage, xanthine 
oxidase activity is not elevated in UC (Simmonds, 1993)
 
but increased nitric 
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oxide synthesis is confirmed in UC (Reynolds, 1996;Hosseini, 2008 ; Colon, 
2004). This pathway involves the reaction of hydrogen peroxide with both L- and 
D-arginine (Nagase, 1997). Conventionally, the activity of nitric oxide synthase 
is thought to be the main factor for NO
•
 generation in UC (Smith, 1993; Hosseini, 
2008). When the large bowel wall becomes inflamed and hypoxic, other 
alternative sources become more important like the reduction of nitrite by 
xanthine oxidase and bacterial nitrate/nitrite reductases as well as the non-
enzymatic reaction of hydrogen peroxide with arginine. Oxygen radicals, 
particularly superoxide and hydroxyl radicals are very reactive species believed 
to be involved in cell and tissue damage in a variety of diseases including 
inflammatory bowel disease (Allgayer, 1991; Colon, 2004). Both CD and UC 
patients showed increased free radical derived DNA damage within peripheral 
leukocytes, by examining the amount of 8-hydroxy-deoxy-guanosine (8-OHdG) 
present in blood and decreased plasma antioxidant defences (Hanauer, 2006; 
D'Odorico, 2001). 
 Oxidant levels increase in IBD along with oxidation of tissue and cytoskeletal 
proteins. Oxidative injury is correlated with disease severity but it is also present 
in substantial amounts in normal appearing mucosa of IBD patients, suggesting 
that oxidative injury does not necessarily lead to tissue injury and is not entirely a 
consequence of tissue injury. Marked actin oxidation (>50%) and NFkappaB 
which appear to result from cumulative oxidative damage was only seen in 
inflamed mucosa, suggesting that oxidant induced cytoskeletal disruption is 
required for tissue injury, mucosal disruption, and IBD flare-up (Keshavarzian, 
2003; Sunil, 2010).  
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Neutrophil accumulation within epithelial crypts and in the intestinal mucosa 
directly correlates with clinical disease activity and epithelial injury in IBD. 
Advances have defined the mechanisms by which neutrophils are activated or 
migrate across endothelial and mucosal epithelial cells. A better understanding of 
this process will likely provide new insights into novel treatment strategies for 
IBD. Especially, activated neutrophils produce reactive oxygen and nitrogen 
species and myeloperoxidase within intestinal mucosa, which induce oxidative 
stress (Naito, 2007). 
Emerging evidence demonstrates that prostaglandins play an important role in 
inflammation and cancer and recently the roles of the different prostaglandins in 
colorectal cancer and IBD have been studied (Sica, 2008). 
 The cyclooxygenase (COX) is a key enzyme in the conversion of arachidonic 
acid to prostaglandins (Park, 2007). 
Intestinal inflammation is accompanied by excessive production of reactive 
oxygen and nitrogen metabolites. In order to counteract their harmful effects, the 
intestinal mucosa contains an extensive system of antioxidants. It has previously 
been shown that the levels of and the balance between the most important 
antioxidants are seriously impaired within the intestinal mucosa from 
inflammatory bowel disease patients compared with normal mucosa (Kruidenier, 
2003; Sunil, 2010). 
Oxidative stress is thought to play a significant role in the pathogenesis of 
inflammatory bowel disease, including CD. In an Italian study, subjects (37 CD 
and 46 UC patients) were compared with 386 healthy controls. Oxidative DNA 
damage was measured by examining the amount of 8-hydroxy-deoxy-guanosine 
(8-OhdG) present in blood. In addition, evaluation of plasma levels of vitamins A 
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and E and carotenoids demonstrated significant decreases in patients with either 
CD or UC when compared to controls. The specific carotene found to be most 
significantly reduced was beta-carotene, with plasma levels at only 50 percent of 
that of the controls. No significant differences were detected between CD and 
UC patients. Levels of 8-OhdG were considerably higher in IBD patients than in 
the controls, indicating increased oxidative DNA damage (Tanaka, 2001). 
Reduced plasma antioxidant concentrations and increased oxidative DNA 
damage were found in IBD (D'Odorico, 2001; Romier, 2009).  
Endogenous antioxidants such as superoxide dismutase (SOD), glutathione, and 
catalase are normally able to counteract oxidative stress in the intestinal mucosa. 
However, inflammation increases the demand for these important antioxidants 
and results in an imbalance between pro-oxidants and antioxidants, with 
subsequent mucosal damage (Jahanshahi,  2004). 
Depletion of antioxidants is likely to be important in the pathophysiology of IBD. 
Ulcerative colitis and CD patients showed increased free radical peripheral 
leukocyte DNA damage and decreased plasma antioxidant defences, by 
examining the amount of 8-hydroxy-deoxy-guanosine (8-OHdG) present in 
blood and decreased plasma antioxidant defences (Hanauer, 2006). This pathway 
involves the reaction of hydrogen peroxide with both L- and D-arginine (Nagase, 
1997; Klink, 2001). Conventionally, the activity of nitric oxide synthase is 
thought to be the main factor for NO
•
 generation in UC (Smith, 1993). When the 
large bowel wall becomes inflamed and hypoxic, other alternative sources 
become more important like the reduction of nitrite by xanthine oxidase and 
bacterial nitrate/nitrite reductases as well as the non-enzymatic reaction of 
hydrogen peroxide with arginine. Oxygen radicals, particularly superoxide and 
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hydroxyl radicals are very reactive species believed to be involved in cell and 
tissue damage in a variety of diseases including inflammatory bowel disease 
(Allgayer, 1991; Keshavarzian, 2003).  
Hypoxia inducible factors 1  and 2  (HIF1  and HIF2 ) are
 
hypoxia regulated 
transcriptional factors, which control the
 
expression of a variety of genes 
responsible for angiogenesis,
 
glycolysis, and the inhibition of apoptosis. Because 
angiogenesis
 
and tissue regeneration are integral components of the inflammatory
 
process, a study was designed to investigate the role of
 
HIF  molecules in 
inflammatory bowel disease (Giatromanolaki, 2003). 
HIF1  was expressed focally (epithelial cells, stromal
 
fibroblasts, and myocytes) 
in both UC and CD, whereas HIF2  was
 
expressed focally in UC and diffusely in 
CD. Thymidine phosphorylase (TP) is the key enzyme for capecitabine activation 
in tumour cells. Thymidine phosphorylase expression was
 
uniformly positive in 
both diseases. VEGF expression vascular endothelial growth factor in healing
 
wounds provokes dermal angiogenesis through complex mechanisms involving
 
promotion of endothelial cell proliferation (Ferrara and Henzel 1989; Zanetti, 
Barozzi et al. 2010). VEGF was absent
 
in CD, and weakly positive in UC. The 
VEGF–KDR reactivity of the submucosal vasculature was only slightly increased 
in
 
UC and CD compared with normal tissue. The inflammatory cells
 
stained with 
HIF2  and TP in all cases, but the reactivity was
 
generalised in CD and focal in 
UC. In both diseases, vascular
 
density was significantly higher than that seen in 
normal tissue (Giatromanolaki, 2003). 
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1.1.3. Genetic disorders 
Mutations in the Nod2 gene may be associated with distinct, phenotypic 
expressions of Crohn's disease. Indeed, genotype/phenotype associations have 
already been identified which suggest that patients with Crohn's disease and 
Nod2 mutations are more likely to have "phenotypic expressions" of ileal disease 
that develop fibrostenosing complications (Abreu, 2002; Huebner, 2010). The 
scientists have shown that the wild-type Nod2 protein is a general sensor of 
peptidoglycan through the recognition of muramyl dipeptide (MDP), the minimal 
bioactive peptidoglycan motif common to all bacteria, and that the 3020insC (a 
cytosine insertion) frameshift mutation variant of Nod2, most frequently 
associated with Crohn's disease, fully abrogates Nod2-dependent detection of 
peptidoglycan and MDP (Abreu, 2002;Marrakchi, 2009).These observations 
have prompted the necessity of further elucidation of genetic patterns and, in 
particular, the likelihood of immune interactions with common enteric bacteria, 
inducing vulnerability to the development of the IBDs, and Crohn's disease in 
particular (Stephen, 2003 ; Haller, 2010).  
The first CD susceptibility gene, NOD2/CARD15 on chromosome 16, was 
characterized (Gao, 2005; Torok, 2009). Other susceptibility genes have since 
been located (Gao, 2005). Their identification should help to understand the 
complex interaction between the environment and the intestinal immune system 
(Colombel, 2007). IBD may cause a delay in puberty or growth problems 
because it can interfere with nutrition. Patients usually need extensive therapeutic 
treatment as a result of the chronic relapsing nature of the disease. Ten percent of 
patients have a first degree relative with the disease while siblings are affected 30 
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times more often than the general population suggesting that genetic factors help 
susceptibility to IBD (Ueda, 1992).  
 
The principal antigenic barrier to transplantation is a series of molecules which 
are polypeptide products of a closely linked cluster of genes known as the Major 
Histocompatibility Complex (MHC) or HLA (for Human Leukocyte Antigens) in 
humans (Jahanshahi, 2004). The MHC is highly polymorphic from individual to 
individual, and segregates in families in a Mendelian codominant fashion.  
 
 
1.1.4. MHC classes  
 The abnormalities of T cells or macrophages and their interaction still remains 
the most feasible hypothesis (Bross, 1996; Guri, 2010). The genes of the HLA 
locus are located on the short arm of chromosome 6 (Suthanthiran, 1994; Chen, 
2010). They encode two distinct classes of cell surface molecules, I and II 
(Duquesnoy, 1988; Ferguson, 2007). Class I molecules are expressed on the 
surfaces of virtually all nucleated cells at varying densities, while class II 
molecules are more restricted to cells of the immune system, primarily B 
lymphocytes and monocytes. However, cytokines secreted by lymphocytes and 
monocytes during immune activation can cause dramatic increases in class II 
HLA antigen expression, even on cell types which normally have little or no 
surface expression (Halloran, 1986; Ebert, 2005). 
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There are three different class I (HLA-A, -B, -C) and class II (HLA-DQ, -DR, -
DP) antigens. Studies in renal transplantation indicate that mismatches at the A, 
B, and DR loci are associated with worse allograft survival (Doxiadis, 1996).  
The normal function of the MHC is now better understood. The principal task of 
the immune system is to distinguish self from non-self.  
HLA molecules provide the crucial surface upon which the antigen receptors on 
T lymphocytes recognize foreign (non-self) antigens. On antigen presenting cells 
such as macrophages, class II molecules present antigenic fragments to the CD4+ 
inducer (or helper) T cells, while class I molecules function at the effector phase 
of immunity by presenting antigens to CD8+ T cells, which generally have 
cytotoxic/suppressor function (Suthanthiran, 1994; Yap, 2004). This process of 
antigen presentation consists of the binding of a single T cell receptor to a 
complex on the surface of an antigen presenting cell consisting of the MHC 
molecule and a peptide fragment derived from the foreign antigen (Figures 1.1.3 
and 1.1.4).  
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Figure 1.1.3. Interaction of HLA and the T cell antigen receptor complex.The T cell antigen 
receptor is composed of an alpha and a beta chain which are linked by disulfide bonds forming a 
heterodimer. The TCR recognizes and interacts with processed peptide antigen {Krensky, 1990 
#7;Krensky, 2005 #35} 
 
The T cell antigen receptor is composed of an alpha and a beta chain which are 
linked by disulfide bonds forming a heterodimer. The TCR recognizes and 
interacts with processed peptide antigen presented in the context of the major 
histocompatibility complex. Adapted from (Krensky, 2005).  
The first CD susceptibility gene, NOD2/CARD15 on chromosome 16, was 
characterized (Gao , 2005). Other susceptibility genes have since been located 
(Gao, 2005). Their identification should help to understand the complex 
interaction between the environment and the intestinal immune system 
(Colombel , 2007).  
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Figure1.1.4. Representation of T-cell activation, Nature Immunology (2001) 
This is a schematic representation of initiation and immunologic response to an 
antigen. The antigen binds to a groove in MHC class II molecules on antigen-
presenting cells (APCs, such as macrophages). This binding allows the antigen to 
be presented to antigen receptors on autoreactive CD4 inducer or helper T cells 
which, in type 1 diabetes mellitus, initiate autoimmune injury to the pancreatic 
beta-cells. In addition, the respective binding of B7 proteins and LFA-3 
(lymphocyte functional antigen-3) on APCs to CD28 and CD2 on T cells are 
important costimulatory pathways that further increase T-cell activation. Other 
molecules also can participate in the immune response, such as the binding of 
interleukin-2 to its receptor (IL-2R) (Krensky, 2005) (Photograph 1.1.4).  
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1.2. Polyposis Coli  
 
A GI polyp is defined as a mass of the mucosal surface protruding into the lumen 
of the bowel. Polyps can be neoplastic, nonneoplastic, or submucosal. GI 
polyposis is characterized by multiple polyps within the GI tract. The adenoma 
and  hyperplastic polyp are two major types of colorectal epithelial polyps (Aust 
and Baretton 2010). The adenomas in the colon and rectum are developed due to 
west countries widespread of familial adenomatous polyposis. The number of 
polyps can range from no detectable polyps at colonoscopy to more than 7,000 
seen on resected specimens of bowel. The polyposis predominantly affects the 
left colon (80-90%) (Debinski, Love et al. 1996). A variety of polyposis 
syndromes can affect the GI tract. These polyposis syndromes may be classified 
as familial inherited (autosomal dominant) or nonfamilial. The inherited 
polyposis syndromes can be further subdivided into 2 groups depending on 
whether the polyps are adenomas or hamartomas. The adenomatous polyposis 
syndromes include the classic familial adenomatous polyposis (FAP) 
(Photographs 1.2.1, 1.2.2) Gardner syndrome, and Turcot syndrome. 
Hamartomatous familial polyposis syndromes include Peutz-Jeghers syndrome, 
juvenile polyposis syndrome, Cowden disease, and Ruval-Caba-Myhre-Smith 
syndrome (Chan and Haghighi 2006; Aust and Baretton 2010). 
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Photograph 1.2.1.Colon, polyposis syndromes. Polyposis coli. Left lateral decubitus image 
obtained as part of a barium enema study shows numerous small polyps in the transverse and 
descending colon. emedicine.medscape.com 
 
 
 
 
Photograph 1.2.2.Colon, polyposis syndromes. Polyposis coli. Double-contrast enema study in a 
man with a family history of familial colonic polyposis shows a solitary polyp with malignant 
change. 
emedicine.medscape.com 
 
1.2.1. Distribution of polyposis coli 
 
FAP is inherited in an autosomal dominant manner with 80% penetrance, but 
sporadic occurrence has been recorded in one third of patients. The gene for FAP 
is located on chromosome 5. The prevalence is quoted as 1 in 7,000-24,000 live 
births. From fly to man, APC is strongly expressed in the developing
 
and adult 
nervous system (Koester, Muller et al. 2007). 
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Gardner syndrome probably has the same genotype as FAP coli. It is transmitted 
as an autosomal dominant trait with complete penetrance and variable 
expressivity. The incidence of familial polyposis of the colon is between 1 in 
8,300 and 1 in 14,025 live births (Nandakumar, Morgan et al. 2004). The 
estimated prevalence is 1 in 14,000 populations (Nannery, Barone et al. 1990).  
Peutz-Jeghers syndrome has a prevalence of 1 in 7,000 live births with a half 
familial and half sporadic distribution. Cronkhite-Canada syndrome has no 
hereditary factors; 100 cases had been published as of 1994. Turcot syndrome is 
inherited in an autosomal recessive manner. Approximately 100 cases of 
Cowden's syndrome have been reported in the literature. Ruval-Caba-Myhre-
Smith syndrome is rare, and the exact incidence is not known (Galiatsatos and 
Foulkes 2006). There is no racial or sex predominance predilection for colonic 
polyps and also it is reported in FAP coli, Gardner syndrome, or Peutz-Jeghers 
syndrome. However, the papillary thyroid carcinoma associated with Gardner 
syndrome has a female preponderance (Kupfer, McCaffrey et al. 2006). 
 
1.2.2. Pathophysiology 
 
Familial adenomatous polyposis (FAP) is the most common adenomatous 
polyposis syndrome. It is an autosomal dominant inherited disorder characterized 
by the early onset of hundreds to thousands of adenomatous polyps throughout 
the colon. If left untreated, all patients with this syndrome develop colon cancer 
by age 35-40 years. In addition, an increased risk exists for the development of 
other malignancies (Lefevre J.H.Colas 2010). MYH associated polyposis is a 
hereditary syndrome, autosomal recessive responsible for early colorectal cancer 
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with a distinct genetic pathway from the Familial Adenomatous Polyposis or the 
Hereditary Non Polyposis Colorectal Cancer syndrome (Lefevre J.H.Colas 2010). 
The genetic defect in FAP is a germline mutation in the adenomatous polyposis 
coli (APC) gene. Syndromes once thought to be distinct from FAP are now 
recognized to be, in reality, part of the phenotypic spectrum of FAP 
(Castellsague, Gonzalez et al. 2010).  
Syndromes with a germline mutation in the APC gene include FAP, Gardner 
syndrome, some families with Turcot syndrome, and attenuated adenomatous 
polyposis coli (AAPC) (Edlich, Cross et al. 2009). Gardner syndrome is 
characterized by colonic polyposis typical of FAP, along with osteomas (bony 
growth most commonly on the skull and the mandible), dental abnormalities, and 
soft tissue tumours. Turcot syndrome is characterized by colonic polyposis 
typical of FAP, along with central nervous system tumours (medulloblastoma). 
The APC is characterized by fewer colonic polyps (average number of polyps, 
30-35) as compared to classic FAP. The polyps also tend to develop at a later age 
(average age, 36 y), and they tend to involve the proximal colonic area (Edlich, 
Cross et al. 2009). 
 
 
1.2.3. Anatomy and clinical presentation 
The groups of symptoms that are shared by all polyposis syndromes include 
vague abdominal pain, rectal bleeding and mild diarrhea, passage of mucus, 
intussusception, rectal prolapse, and bowel obstruction. GI symptoms of rectal 
bleeding and abdominal pain usually develop in the third decade in FAP (Cappell 
2007). 
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Photograph 1.2.3. 4,272 × 2,848 pixels, file size: 4.47 MB, MIME type: image/jpeg. Micrograph 
of a tubular adenoma (left of image), a type of colonic polyp and a precursor of colorectal cancer. 
Normal colorectal mucosa is seen on the right. H&E stain. emedicine.medscape.com 
The process of developing colon cancer from adenomas polyp is a multistep, 
relating to mutations of the DCC, k-ras, and p53 genes; loss of heterozygosity in 
which cells loose one allele of some genes from chromosomal loss; and DNA 
methylation which can silence DNA expression. While colon cancer in an 
advanced and incurable stage often produces clinical findings, premalignant 
adenomatous polyps (Photograph 1.2.3) and early, highly curable, colon cancer 
are often asymptomatic (Cappell 2007). 
 
1.2.4. Treatment 
The colorectal lesions in early stage prone to cancer can be detected and removed 
by colonoscopic screening test. The strong controversy is to decide when 
endoscopic treatment is enough or when surgical resection is necessary (Ruiz-
Tovar, Jimenez-Miramon et al. 2010). In addition, metformin suppresses colonic 
epithelial proliferation via the inhibition of the mTOR (mammalian target of 
rapamycin) pathway through the activation of AMPK (adenosine 
monophosphate-activated protein kinase). As metformin is already used daily as 
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an antidiabetic drug, it might be a safe and promising candidate for the 
chemoprevention of colorectal cancer (Hosono, Endo et al. 2010). 
 
 
 
1.3. Colorectal cancer  
 
Colorectal cancer, also called colon cancer large intestine cancer or large bowel 
cancer, includes cancerous growths in the colon, in the last six inches of the 
colon (the rectum) and appendix it is the fourth most common form of cancer in 
the United States and the third leading cause of cancer-related death in the 
Western world (WHO 2006). The large bowel cancer (also known as colorectal 
cancer) is a common form of malignancy in developed countries and Colon and 
rectal cancer incidence was negligible before 1900. The incidence of colorectal 
cancer has been rising dramatically following economic development and 
industrialization but occurs much less frequently in the developing world. 
Around 106 new cases of colorectal cancer are diagnosed each day in the UK and 
it is the third most common cancer after breast and lung. In 2007 there were 
38,608 new cases of large bowel cancer registered in the UK: around two-thirds 
(24,274) in the colon and one-third (14,334) in the rectum (Registry 2010; 
Statistics 2010) (Figure 1.3.1).  
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Figure1.3.1. Correlation between meat consumption and colon cancer rates in different countries. 
emedicine.medscape.com 
 
 
 
Photograph 1.3.1. Colorectal cancer endoscopy: 473 × 456 pixels, file size: 141 KB, MIME type: 
image/jpeg. en.wikipedia.org/wiki/Colorectal_cancer 
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Photograph 1.3.2.Gross appearance of a colectomy specimen containing one invasive colorectal 
carcinoma (the crater-like, reddish, irregularly shaped tumour). en.wikipedia.org/wiki/Colorectal_cancer 
 
Colorectal cancers arise from adenomatous polyps in the colon. These 
mushroom-shaped growths are usually benign, but some develop into cancer 
over time. Localized colon cancer is usually diagnosed through colonoscopy 
(Photograph 1.3.1). Invasive cancers that are confined within the wall of the 
colon (TNM stages I and II) are curable with surgery. If untreated, they spread to 
regional lymph nodes (stage III), where up to 73% are curable by surgery and 
chemotherapy (Photograph 1.3.2). Cancer that metastasizes to distant sites (stage 
IV) is usually not curable, although chemotherapy can extend survival, and in 
rare cases, surgery and chemotherapy together have seen patients through to a 
cure (Markowitz and Bertagnolli 2009). Radiation is used with rectal cancer. At 
the cellular and molecular level, colorectal cancer starts with a mutation to the 
Wnt signaling pathway. Therefore, the Wnt binds to a receptor on the cell that 
sets in motion a chain of molecular events that ends with β-catenin moving into 
the nucleus and activating a gene on DNA. In colorectal cancer, genes along this 
chain are damaged. Usually, a gene called APC, which is a "brake" on the Wnt 
pathway, is damaged. Without a working APC brake, the Wnt pathway is stuck 
in the "on" position (Markowitz and Bertagnolli 2009). 
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1.3.1. Signs and symptoms 
Unfortunately, most people with colorectal cancer do not experience any 
symptoms in the early stage of the disease. That's why screening tests, such as a 
colonoscopy, are so important (Le Marchand, Wilkens et al. 1999).The 
symptoms of colorectal cancer depend on the location of the tumour in the bowel, 
and whether it has spread elsewhere in the body. Most of the symptoms may 
occur in other diseases as well, and hence none of the symptoms mentioned here 
is diagnostic of colorectal cancer. Changes in bowel habits for example, blood in 
the stool (can have other causes, too), problems related to blood loss (anemia, 
weakness, fatigue, shortness of breath, pounding or racing heart, chest pain, and 
intolerance to exercise), abdominal discomfort (frequent gas, bloating, fullness, 
cramps, and pain), unexplained weight loss, pain with bowel movement and 
feeling that the bowel doesn't empty completely (Fauci ,  2008). 
There are two different types of signs and symptoms  local and constitutional 
(Carrion, Marin et al. 2010).  
 
1.3.1. 1. Local 
Local symptoms are more likely if the tumour is located closer to the anus. There 
may be a change in bowel habit (new-onset constipation or diarrhea in the 
absence of another cause), and a feeling of incomplete defecation (rectal 
tenesmus) and reduction in diameter of stool; tenesmus and change in stool shape 
are both characteristic of rectal cancer. Lower gastrointestinal bleeding, 
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including the passage of bright red blood in the stool, may indicate colorectal 
cancer, as may the increased presence of mucus. Melena, black stool with a tarry 
appearance, normally occurs in upper gastrointestinal bleeding (such as from a 
duodenal ulcer), but is sometimes encountered in colorectal cancer when the 
disease is located at the beginning of the large bowel. 
A tumour that is large enough to fill the entire lumen of the bowel may cause 
bowel obstruction. This situation is characterized by constipation, abdominal 
pain, and abdominal distension and vomiting. This occasionally leads to the 
obstructed and distended bowel perforating and causing peritonitis. 
Certain local effects of colorectal cancer occur when the disease has become 
more advanced. A large tumor is more likely to be noticed on feeling the 
abdomen, and it may be noticed by a doctor on physical examination. The 
disease may invade other organs, and may cause blood or air in the urine 
(invasion of the bladder) or vaginal discharge (invasion of the female 
reproductive tract). 
 
1.3.1.2. Constitutional 
If a tumour has caused chronic occult bleeding, iron deficiency anemia may 
occur; this may be experienced as fatigue, palpitations and noticed as pallor (pale 
appearance of the skin). Colorectal cancer may also lead to weight loss, generally 
due to a decreased appetite. 
 70 
More unusual constitutional symptoms are an unexplained fever and one of 
several paraneoplastic syndromes. The most common paraneoplastic syndrome is 
thrombosis, usually deep vein thrombosis. 
1.3.1.3. Metastatic 
Colorectal cancer most commonly spreads to the liver. This may go unnoticed, 
but large deposits in the liver may cause jaundice and abdominal pain (due to 
stretching of the capsule). If the tumour deposit obstructs the bile duct, the 
jaundice may be accompanied by other features of biliary obstruction, such as 
pale stools (Partelli, Mukherjee et al. 2010). 
1.3.2. Risk factors 
Risk factors for colorectal cancer include, age (being over 50) (Prevention, 2010) 
having colorectal cancer previously and a history of adenomatous polyps or 
family history of colorectal cancer (Nieuwenhuis, Douma et al. 2010; Slattery, 
Herrick et al. 2010), eating a high-fat diet, smoking, being overweight (Wernli, 
Newcomb et al. 2010), heavy use of alcohol,  inflammatory bowel disease, 
diabetes (Pais, Silaghi et al. 2009; Campbell, Deka et al. 2010). The exposure to 
some viruses (such as particular strains of human papilloma virus) may be 
associated with colorectal cancer (Bean, Chhieng et al. 2010). The style of 
infection and following that transformation resembles very much the 
pathogenesis of cervical and other HPV-associated cancers (Bean, Chhieng et al. 
2010; von Knebel Doeberitz and Reuschenbach 2010). Recent trends in some of 
the western countries suggest a disproportionally higher incidence and death 
from colon cancer in African Americans (AAs) than in whites. Hispanic persons 
have the lowest incidence and mortality from colorectal cancer and an increased 
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prevalence of polyps has also been noted in men regardless of race (Penn, 
Garrow et al. 2010). 
 
 
 
Photograph 1.3.3. Micrograph of a colorectal adenocarcinoma metastasis to a lymph node. The 
cancerous cells are at the top center-left of the image, in glands (circular/ovoid structures) and 
eosinophilic (bright pink). H&E stain. en.wikipedia.org/wiki/Colorectal_cancer 
 
 
1.3.3. Diagnosis 
The doctor will take a complete medical history, and will perform a physical 
examination to order one or more tests to diagnose colorectal cancer. Standard 
tests used to diagnose colorectal cancer include sigmoidoscopy, colonoscopy, 
and barium enema (Taouqi, Ingrand et al. 2010). 
 During a sigmoidoscopy or a colonoscopy, a biopsy (sample of tissue) is 
removed  
from the colon or rectum and examined under a microscope in order to detect  
abnormal growths (Photograph 1.3.3) 
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Stages of colorectal cancer include: 
Stage 0: The earliest stage; cancer is found only in the innermost lining of the 
colon and/or rectum. 
Stage 1: Cancer has grown through the innermost lining but hasn't spread beyond 
the colon wall or rectum. 
Stage 2: Cancer has spread to deeper layers of the wall of the colon or rectum, 
but not the lymph nodes. 
Stage 3: Cancer has spread to nearby lymph nodes but not to other parts of the 
body. 
 Stage 4: Cancer has spread to other parts of the body, such as the liver and lungs 
(Fauci , 2008). Dukes system (Table 1.3.1) 
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1.3.5. Preventive Care 
Regular screening for colorectal cancer can prevent, even cure, when it is in a 
very early stage. Detecting polyps before they become cancerous allows the 
patients to survive with in situ colorectal cancer. Regular screening is operated at 
age 50 for people who have an average risk of for colorectal cancer (Lieberman, 
2008). Eating plenty of fruits and vegetables as well as foods rich in omega-3 
fatty acids (such as salmon and halibut) and calcium (such as sea vegetables and 
kale) can help reduce the risk of colorectal cancer. Limiting alcohol consumption, 
quitting smoking, and reducing the intake of high-fat and fried foods, particularly 
red meats, may also protect developing colorectal cancer (Barros, Xavier et al. 
2010; Limsui, Vierkant et al. 2010). 
 
1.3.6. Pathogenesis 
 
The most common colon cancer cell type is adenocarcinoma which accounts for 
95% of cases. Other, rarer types include lymphoma and squamous cell carcinoma. 
Genetically, colorectal cancer represents a complex disease, and genetic 
alterations are often associated with progression from premalignant lesion 
AJCC 
stage 
TNM stage  
 
Stage 0 Tis N0 M0 Tis: Tumour confined to mucosa; cancer-in-situ 
Stage I T1 N0 M0 T1: Tumour invades submucosa 
Stage I T2 N0 M0 T2: Tumour invades muscularis propria 
Stage II-A T3 N0 M0 
T3: Tumour invades subserosa or beyond (without other 
organs involved) 
Stage II-B T4 N0 M0 
T4: Tumour invades adjacent organs or perforates the 
visceral peritoneum 
Stage III-A T1-2 N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T1 or T2. 
Stage III-B T3-4 N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T3 or T4. 
Stage III-C any T, N2 M0 N2: Metastasis to 4 or more regional lymph nodes. Any T. 
Stage IV 
any T, any N, 
M1 
M1: Distant metastases present. Any T, any N. 
Table 1.3.1.TNM stage criteria for colorectal cancerAJCC Cancer Staging Manual (Sixth ed.). Springer-Verlag 
New York, Inc.. 2002 
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(adenoma) to invasive adenocarcinoma. Sequence of molecular and genetic 
events leading to transformation from adenomatous polyps to overt malignancy 
has been characterized in other studies (Goel and Boland 2010).
 
 The early event 
is a mutation of APC (adenomatous polyposis gene), which was first discovered 
in individuals with familial adenomatous polyposis (FAP). The protein encoded 
by APC is important in activation of oncogene c-myc and cyclin D1, which 
drives the progression to malignant phenotype. Although FAP is a rare hereditary 
syndrome accounting for only about 1% of cases of colon cancer, APC mutations 
are very frequent in sporadic colorectal cancers (Velmurugan, Gangar et al. 
2010). Genome-wide association studies have recently linked CRC to 10 
common genetic variants or single-nucleotide polymorphisms that map to 
chromosomes 8q23, 8q24, 10p14, 11q23, 14q22, 15q13, 16q22, 18q21, 19q13 
and 20p1. Recent studies indicate that the single-nucleotide polymorphism 
rs6983267, which maps to 8q24, serves as an enhancer of MYC expression by 
binding T cell factor 4 (TCF4) and influencing Wnt signalling (Goel, 2010).  
Other important genes in colon carcinogenesis include KRAS oncogene, 
chromosome 18 loss of heterozygosity (LOH) leading to inactivation of SMAD4 
(DPC4), and DCC (deleted in colon cancer) tumour suppression genes (Koyama, 
Ito et al. 1999). Chromosome arm 17p deletion and mutations affecting p53 
tumour suppressor gene confer resistance to programmed cell death (apoptosis) 
and are thought to be late events in colorectal cancer (Risio, Casorzo et al. 2003). 
This phenotype has been linked to mutations of genes such as MSH2, MLH1, and 
PMS2. These mutations result in so-called high frequency microsatellite 
instability (H-MSI), which can be detected with an immunocytochemistry 
assay. H-MSI is a hallmark of hereditary nonpolyposis colon cancer syndrome 
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(HNPCC, Lynch syndrome), which accounts for about 6% of all colon cancers. 
H-MSI is also found in about 20% of sporadic colon cancers (Hall, Clarkson et al. 
2010; Sjursen, Haukanes et al. 2010). 
 
1.3.7. Treatment 
Surgery to remove the part of the colon containing tumour is the primary 
treatment. Depending on the stage of the cancer, surgery is generally followed 
with chemotherapy (Jenab-Wolcott and Giantonio 2010). If the tumour is 
particularly large, radiation may be needed before or after surgery. An unhealthy 
lifestyle can increase the risk of developing the colorectal cancer by as much as 
70% for some people (Young and Le Leu 2002). Many studies support that doing 
exercise by preventing colon tumorigenesis, at least partly via the suppression of 
iNOS expression associated with anti-inflammation (Aoi, Naito et al. 2010). 
Antioxidant foods, should be eaten including fruits (such as blueberries, cherries, 
and tomatoes), and vegetables (such as squash and bell peppers) and all high 
doses of hydrolyzed soybean treatments, except the green genotype significantly 
reduce colorectal cancer cell numbers compared to control reduction (Slavin, 
Kenworthy et al. 2009). 5-Fluorouracil remains the backbone of chemotherapy 
regimens for colon cancer, both in the adjuvant and metastatic setting (Boni, 
Bitarte et al. 2010). In addition to 5-fluorouracil, oral fluoropyrimidines such as 
capecitabine (Xeloda) and tegafur are increasingly used as monotherapy or in 
combination with oxaliplatin (Eloxatin) and irinotecan (Camptosar) and 
Leucovorin (LV, folic acid). Some of the standard combination regimens employ 
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prolonged continuous infusion of fluorouracil (FOLFIRI, FOLFOX)
 
or 
capecitabine (CAPOX, XELOX, XELIRI) (Tournigand, Andre et al. 2004).  
 
1.3. Melanocytic nevus, suspected melanoma 
 
A nevus is a benign (non-cancerous) melanocytic tumour, more commonly called 
a mole. The American Academy of Dermatology announced that the majority of 
moles occure during the first two decades of a person’s life, while about one in 
every 100 babies is born with moles (AAD. 2008)
. 
Nevi are not usually present at 
birth but begin to appear in children and teenagers. Most moles will never cause 
any problems, but a person who has more than 50 normal moles (or more than 5 
atypical or "dysplastic" moles) has a higher risk of developing melanoma, the 
most aggressive form of skin cancer (Photograph 1.4.1). The number of 
melanocytic nevi is the strongest risk factor for cutaneous melanoma. As 
pigmented skin lesions are visible to everybody (Buettner and Garbe 2000) and 
cautiously detecting the suspicious lesions can expand the microscopic 
pathological data in the determination of prognosis also, these skin lesions, 
suspected to be melanoma should be photographed. The photograph and 
pathological report if it is followed up after surgical removal of the lesion could 
be a strong clue in the patient's permanent medical record (Hosono, Endo et al. 
2010).  
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Photograph 1. 4.1. A normal mole, Photo © National Cancer Institute 
 
1.4.1. Sign and symptoms 
1.4.1.1. Location 
There are different types of nevi based on the location of the melanocyte cells. 
The junctional nevus is which the nevus cells are located along the junction of 
the epithelium and the underlying dermis. A junctional nevus is flat and brown to 
black.  
The other type is a compound nevus which is a mixture of junctional and 
intradermal proliferation. Compound nevi are slightly raised and brown to black. 
Beauty marks are usually compound nevi of either the acquired variety or 
congenital variety.  
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The last one is the intradermal nevus with cells located in the dermis only. 
Intradermal nevi are raised; most are flesh-colored (not pigmented) (Gutierrez, 
Barengo et al. 2009).  
 
1.4.1.2. Dysplastic nevus   
 Dysplastic naevi (DN) are a known risk factor for malignant melanoma which is 
categorised to suspected melanoma. Their occurrence is closely connected with 
the degree of skin pigmentation though people with a light complexion are more 
likely to develop DN than dark-skinned individuals. DN cells contain higher 
concentrations of radical oxygen species than normal skin melanocytes from the 
same individuals also the increase of phaeomelanogenesis in DN cells is 
connected with oxidative imbalance, which is reflected by increased intracellular 
concentrations of reactive oxygen species and raised calcium and iron 
concentrations (Pavel, 2004).  
The compound nevus with cellular and architectural dysplasia is a dysplastic 
nevus. Like typical moles, dysplastic nevi can be flat or raised. While they vary 
in size, dysplastic nevi are typically larger than normal moles and tend to have 
irregular borders and irregular coloration (Shrestha, Bishop et al. 2010). Hence, 
they resemble melanoma, appear worrisome, and are often removed to clarify the 
diagnosis. Dysplastic nevi are markers of risk when they are numerous (atypical 
mole syndrome). According to the National Cancer Institute (NIH), doctors 
believe that dysplastic nevi are more likely than ordinary moles to develop into 
the most virulent type of skin cancer called melanoma.  
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Oncogenic BRAF as an early and fundamental feature of melanocytic neoplasia 
has been confirmed with its identification in both melanoma and nevi. Oncogenic 
BRAF induces senescence/apoptosis by up-regulating the tumour suppressor 
IGFBP7, which acts through autocrine/paracrine pathways to inhibit BRAF-
MEK-ERK signalling (Decarlo, Yang et al. 2010). 
1.4.2.3. Blue nevus 
 It is blue in color as its melanocytes are very deep in the skin. The nevus cells 
are spindle shaped and scattered in deep layers of the dermis. The covering 
epidermis is normal (Lee, Na et al. 2010).  
1.4.2.4. Spitz nevus 
 The distinct variant of intradermal nevus is found usually in children. They are 
raised and reddish (non-pigmented). A pigmented variant, called the nevus of 
Reed, typically appears on the leg of young women (Blum 2010; LeAnder, 
Chindam et al. 2010).  
1.4.2.5. Acquired nevus 
 Acquired nevus is any melanocytic nevus that is not a congenital nevus or not 
present at birth or near birth. This includes junctional, compound and intradermal 
nevus. Damaged keratinocytes and inflammatory cells can release growth factors 
inducing nevus cell proliferation, and immunosuppression could end cellular 
surveillance keeping pre-existing nevus cell nests in check (Navarini, Kolm et al. 
2010) (Photograph1.4.1).  
1.4.2.6. Congenital nevus 
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Small to large nevus present at or near the time of birth. Small ones have low 
potential for forming melanomas; however the risk increases with size, as in the 
giant pigmented nevus. Congenital melanocytic nevi (CMNs) are diagnosed in 
1% of newborn infants (Turkmen, Isik et al. 2010). 
 
1.4.2.7. Giant pigmented nevus 
 
 These large, pigmented, often hairy congenital nevi are rare, with an estimated 
incidence of approximately 1 in 20,000 live births. They are important because 
melanoma may occasionally (10 to 15%) appear in them (Chien, Niu et al. 2010) 
(Photograph 1.4.1).  
1.4.2.8. Intramucosal nevus 
 It is a Junctional nevus of the mucosa of the mouth or genital areas. In the 
mouth, they are found most frequently on the hard palate with 
pseudoepitheliomatous hyperplasia of the gingival (Suzuki, Kumamoto et al. 
2002).  
The other types of nevus are nevus of Ito and Nevus of Ota, Mongolian spot and 
recurrent nevus .  
1.4.3. Genetics 
Dysplastic nevi and atypical mole syndrome are hereditary conditions which 
causes a person to have a large quantity of moles (often 100 or more) with some 
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larger than normal or atypical. This often leads to a higher risk of melanoma, a 
serious skin cancer (Burkhart 2003). Developing a cancer more frequently 
happens in dysplastic nevi than ordinary moles. Dysplastic nevi are common and 
having more than 50 ordinary moles increases the risk of developing melanoma 
(Institute 2008). The Single nucleotide polymorphisms (SNP) on chromosomes 9 
and 22 are associated with increased numbers of nevi. The importance of nevi in 
melanoma is the pathogenesis and increases understanding of their genetic 
determinants (Newton-Bishop, Chang et al. 2010). 
1.4.4. Sunlight 
The UV exposure from sun causes premature aging and skin damage that can 
lead to melanoma. The excessive exposure to sunlight, may play a role in the 
formation of acquired moles (van Schanke, van Venrooij et al. 2006).
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1.5. Malignant Melanoma 
 
 
 Malignant melanoma is the most lethal form of skin cancer, which has become 
an important public health issue because in the U.K. over 8,000 cases are 
currently diagnosed each year and the numbers are steadily rising. Worldwide, 
the number of new cases of melanoma is increasing faster than for any other 
cancer type and mortality due to melanoma is also rising (Vasquez-Moctezuma, 
2010). Such cells are found predominantly in skin, but are also found in the 
bowel and the eye (see uveal melanoma). Melanoma is one of the less common 
types of skin cancer, but causes the majority (75%) of skin cancer related deaths. 
These figures make melanoma an important cancer for study (Physician 2000). 
The majority of melanomas arise sporadically but in about 5% of cases there is a 
history of melanoma in two or more close relatives (Psaty, Scope et al. 2010).  
 
 
 
1.5.1. Classification 
 
1.5.1.1. Lentigo maligna 
 
Lentigo maligna is known as lentiginous melanoma on sun-damaged skin. It is a 
melanoma in situ. It consists of malignant cells but does not show invasive 
growth (Erickson and Miller 2010). It is normally found in the elderly (peak 
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incidence in the 9th decade), on skin areas with high levels of sun exposure like 
the face and forearms. Some authors do not consider lentigo maligna to be a 
melanoma. The incidence of evolution to lentigo maligna melanoma is very low, 
about 2.2% to 5% in elderly patients (Erickson and Miller 2010). 
1.5.1.2. Superficial spreading melanoma 
Superficial spreading melanoma is usually characterized as the most common 
form of cutaneous melanoma in Caucasians. The average age at diagnosis is in 
the fifth decade, and it tends to occur on sun-exposed skin, especially on the 
backs of males and lower limbs of females (Amerio, Manzoli et al. 2009). The 
other types of MM are acral lentiginous melanoma, mucosal melanoma, nodular 
melanoma, polypoid melanoma , desmoplastic melanoma, amelanotic melanoma 
and soft-tissue melanoma.  
1.5.2. Signs and symptoms 
Early signs of melanoma are changes to the shape or color of existing moles. At 
later stages, the mole may itch, ulcerate or bleed. Early signs of melanoma are 
summarized as, asymmetry of the borders (irregular), color (variegated), and 
diameter (greater than 6 mm (0.24 in) (picture 1.5.5), about the size of a pencil 
eraser). Metastatic melanoma may cause non-specific paraneoplastic symptoms 
including loss of appetite, nausea, vomiting and fatigue. Metastasis of early 
melanoma is possible. However, fortunately less than a fifth of melanomas 
diagnosed early become metastatic (de la Fuente-Garcia and Ocampo-Candiani 
2010). 
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1.5.3. Aetiology  
 
There is the possibility of involving a multistep process of progressive genetic 
mutations that could be the alter cell proliferation, differentiation, and death and 
impact susceptibility to the carcinogenic effects of ultraviolet radiation 
(Demierre and Nathanson 2003).
 
Recent data suggest multiple pathways of 
melanoma pathogenesis, with melanomas in sun-protected skin (trunk) 
developing in association with a high nevus count and intermittent ultraviolet 
radiation as opposed to those developing on sun-exposed skin in patients with 
low nevus counts and chronic sun exposure (Maldonado, Fridlyand et al. 2003; 
Whiteman, Watt et al. 2003).
 
Primary cutaneous melanoma may develop in 
precursor melanocytic nevi (i.e., common, congenital, and atypical/dysplastic 
types), although more than 60% of cases are believed to arise de novo (i.e., not 
from a pre-existing pigmented lesion). Although the melanoma’s development is 
multifactorial and related to multiple risk factors, for example fair complexion, 
excessive childhood sun exposure and blistering childhood sunburns, an 
increased number of common and dysplastic moles, a family history of 
melanoma, the presence of a changing mole or evolving lesion on the skin, and, 
importantly, older age (Califano and Nance 2009). 
1.5.3.1. Genetics 
Familial melanoma is genetically heterogeneous and loci for familial melanoma 
have been identified on the chromosome arms 1p, 9p and 12q. Multiple genetic 
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events have been related to the pathogenesis of melanoma (Yang, Liang et al. 
2010). The multiple tumour suppressor 1 (CDKN2A/MTS1) gene encodes 
p16INK4a - a low-molecular weight protein inhibitor of cyclin-dependent protein 
kinases (CDKs) - which has been localized to the p21 region of human 
chromosome 9. Today, melanomas are diagnosed only after they become visible 
on the skin. In the future, however, physicians will hopefully be able detect 
melanomas based on a patient’s genotype, not just his or her phenotype (Ibarrola-
Villava, 2010). Recent genetic advances promise to help doctors to identify 
people with high-risk genotypes and to determine which of a person’s lesions 
have the greatest chance of becoming cancerous. A number of rare mutations, 
which often run in families, are known to greatly increase one’s susceptibility to 
melanoma. One class of mutations affects the gene CDKN2A (Ibarrola-Villava, 
2010). An alternative reading frame mutation in this gene leads to the 
destabilization of p53, a transcription factor involved in apoptosis and in fifty 
percent of human cancers. Another mutation in the same gene results in a non-
functional inhibitor of CDK4, a [cyclin-dependent kinase] that promotes cell 
division. Mutations that cause the skin condition Xeroderma Pigmentosum (XP) 
also seriously predispose one to melanoma. Scattered throughout the genome, 
these mutations reduce a cell’s ability to repair DNA. Both CDKN2A and XP 
mutations are highly penetrant. Other mutations confer lower risk but are more 
prevalent in the population. People with mutations in the MC1R gene, for 
example, are two to four times more likely to develop melanoma than those with 
two wild-type copies of the gene. MC1R mutations are very common; in fact, all 
people with red hair have a mutated copy of the gene. Two-gene models of 
melanoma risk have already been created, and in the future, researchers hope to 
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create genome-scale models that will allow them to predict a patient’s risk of 
developing melanoma based on his or her genotype (Ibarrola-Villava, Fernandez 
et al. 2010). In addition to identifying high-risk patients, researchers also want to 
identify high-risk lesions within a given patient. Many new technologies, such as 
optical coherence tomography (OCT), are being developed to accomplish this. 
OCT allows pathologists to view 3-D reconstructions of the skin and offers more 
resolution than past techniques could provide. In vivo confocal microscopy and 
fluorescently tagged antibodies are also proving to be valuable diagnostic tools. 
Mutation of the MDM2 SNP309 gene is associated with increased risk of 
melanoma in younger women (Capasso, Ayala et al. 2010) (Photograph 1.5.1).  
1.5.3.2. UV exposure and malignant melanoma 
 
The incidence of skin cancer has increased due to the increase in the amount of 
ultraviolet-B (UV-B) exposure as a result of ozone reduction across the world 
(Chang, Feng et al. 2010). The S100B-p53 protein complex was discovered in 
C8146A malignant melanoma (MM), therefore reducing S100B expression with 
siRNA and it was sufficient to activate p53 (Lin, Yang et al. 2010). Xeroderma 
pigmentosum (XP) patients have a 1,000-fold higher incidence of melanoma due 
to sunlight-induced "bulky" photoproducts to make melanomagenesis (Wang, 
Choi et al. 2010). Sunlight induces a high level of reactive oxygen species in 
melanocytes (MCs) then oxidative DNA damage (ODD) may also contribute to 
melanomagenesis, and XP gene products may participate in the repair of ODD. 
The melanin sensitizes UVA in the induction of ODD but not bulky UV 
photoproducts and the high susceptibility to UVA-induced ODD and the reduced 
DNA repair capacity in MCs contribute to carcinogenesis also the reduced repair 
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capacity for ODD contributes to the high melanoma incidence in XP patients 
(Wang, 2010). The skin aging process, implying oxidative stress, is associated 
with specific gene expression. Ultraviolet A (UVA) and hydrogen peroxide H2O2 
both generate reactive oxygen species (ROS) making them relevant in the study 
of skin cell responses to oxidative stresses (Hazane-Puch, 2010). Melanocytes 
are producing melanin after UV irradiation as a defence mechanism. However, 
UV-induced damage is involved in melanoma initiation, depending on skin photo 
type. Melanocytes seem to be extremely susceptible to free radicals. Their main 
enzymatic antioxidants are superoxide dismutase and catalase (Baldea, 2009). 
 
Photograph 1.5.1. A malignant melanoma lesion 
 
 
1.5.4. Diagnosis 
To detect melanomas it is important to check for changes (shape, size, color, 
itching or bleeding) in the moles and to show any suspicious moles to a doctor 
with an interest and skills in skin malignancy (Friedman, 1985 ; Torrens, 2009).  
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A popular method for remembering the signs and symptoms of melanoma is the 
mnemonic "ABCDE": 
 Asymmetrical skin lesion.  
 Border of the lesion is irregular.  
 Color: melanomas usually have multiple colors.  
 Diameter: moles greater than 6 mm are more likely to be melanomas than 
smaller moles.  
 Enlarging: enlarging or evolving (Photograph 1.5.7). 
Seborrhea keratosis also in the ABCD criteria can lead to false positive signs 
sometimes even for physicians. An experienced doctor can generally distinguish 
seborrhea keratosis from melanoma upon examination, or with dermatoscopy 
(Califano, 2009 ; Torrens, 2009). 
There is another E which stands for elevation. Elevation can help identify a 
melanoma, but lack of elevation does not mean that the lesion is not a melanoma. 
Most melanomas are detected in the very early stage, or in the in-situ stage, 
before they become elevated. By the time elevation is visible, they may have 
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progressed to the more dangerous invasive stage (Torrens, 2009; Muller, 2009). 
The other well-known sign novel method of melanoma detection is the "Ugly 
Duckling Sign" It is simple, easy to teach, and highly effective in detecting 
melanoma. Simply, correlation of common characteristics of a person's skin 
lesion is made. Lesions which greatly deviate from the common characteristics 
are labelled as an "Ugly Duckling", and further professional examination is 
required (Grob and Bonerandi 1998). However, molecular analysis has 
demonstrated different patterns of cell death, oncogene expression, gene 
amplification, and BRAF mutation frequency among the 4 main histogenetic 
types (Miracco, Santopietro et al. 1998; Bastian, Kashani-Sabet et al. 2000; 
Sasaki, Niu et al. 2004).  
 
1.5.4.1. Superficial spreading melanoma  
Superficial spreading melanoma (SSP) is characterized as the most common on 
the trunk in men and women and on the legs in women; this subtype is most 
commonly seen in individuals aged 30-50 years (photograph 1.5.2).  
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Photograph 1.5.2.Superficial spreading melanoma, left breast, 1.3-mm Breslow 
depth. 
In addition, SSP manifests as a flat or slightly elevated brown lesion with 
variegate pigmentation (i.e., black, blue, pink, or white discoloration) (Demierre, 
Chung et al. 2005). It is generally greater than 6 mm in diameter, however, there 
are a lot of moles as lesions smaller than 6 mm in diameter with melanoma 
(Abbasi, Shaw et al. 2004). Histologically, it is characterized by buckshot 
(pagetoid) scatter of atypical melanocytes within the epidermis (Richard, 1999). 
 
1.5.4.2. Nodular melanoma 
 
Nodular melanoma is the subtype found in 15-30% of patients and it is seen most 
commonly on the legs and trunk. Additionally, it occurs with rapid growth over 
weeks to months and this subtype is responsible for most thick melanomas 
(Demierre, Chung et al. 2005). The colour of the lesions is dark brown-to-black 
papule or dome-shaped nodule, which may ulcerate and bleed with minor 
trauma; it may be clinically amelanotic (i.e., not pigmented) (Torrens and Swan 
2009).  
It tends to lack the typical ABCDE melanoma warning signs and, thus, may 
elude early detection. More commonly, it exhibits elevation, ulceration with 
bleeding, or both at presentation and also in histology (Photograph 1.5.8); it lacks 
a radial growth phase. 
1.5.4.3. Lentigo maligna melanoma  
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One of the lentigo maligna melanoma characteristics is the incidence of lentigo 
maligna subtypes (in situ and invasive) which appears to be rising in the United 
States (Swetter, Boldrick et al. 2005).
 
It is typically located on the head, neck, 
and arms (chronically sun-damaged skin) of fair-skinned older individuals 
(average age 65 y). It grows slowly over 5-20 years (Photograph 1.5.3).  
 
 
 
Photograph 1.5.3.Lentigo maligna melanoma, right lower cheek. Centrally located 
erythematous papule represents invasive melanoma with surrounding macular 
Lentigo maligna (melanoma in situ) 
The in situ precursor lesion is usually large (>1-3 cm in diameter), present for a 
minimum of 10-15 years, and demonstrates macular pigmentation ranging from 
dark brown to black, although hypo pigmented (white) areas are common within 
lentigo maligna. Dermal invasion (progression to lentigo maligna melanoma) is 
characterized by the development of raised blue-black nodules within the in situ 
lesion.  
From a histological viewpoint, it is characterized by a predominantly junctional 
confluent proliferation of melanocytes and extension along adnexal structures. 
Solar elastosis is typically prominent (Swetter, Boldrick et al. 2005). 
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1.5.4.4. Acral lentiginous melanoma  
 This type of malignant melanoma is the least common subtype of melanoma (2-
8% of melanoma cases in white persons) and it accounts for 29-72% of 
melanoma cases in dark-skinned individuals (i.e., African American, Asian, and 
Hispanic persons) and, because of delays in diagnosis, may be associated with a 
worse prognosis (Byrd, Wilson et al. 2004).
 
 
Acral lentiginous melanoma occurs on the palms, on the soles, or beneath the 
nail plate (Subungual variant) (Photograph 1.5.4).  
 
 
 
Photograph 1.5.4. Acral lentiginous melanoma (1-mm Breslow depth), left sole. 
Diagnostic punch biopsy site is located superiorly  
Another type of melanoma is subungual melanoma and may manifest as diffuse 
nail discoloration or a longitudinal pigmented band within the nail plate. It must 
be differentiated from a benign junctional melanocytic nevus of the nail bed, 
which has a similar appearance. Pigment spread to the proximal or lateral nail 
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folds is termed the Hutchinson sign, which is a hallmark for acral lentiginous 
melanoma. 
Rare melanoma variants (<5% of melanomas) include (1) 
desmoplastic/neurotropic melanoma, (2) mucosal (lentiginous) melanoma, 
(Rogers and Gibson 1997)
 
(3) malignant blue nevus, (4) melanoma arising in a 
giant congenital nevus, and (5) melanoma of soft parts (clear cell sarcoma). 
 
 
 
 
 
1.5.5. Race 
 
Melanoma is primarily a malignancy of white individuals. African American 
persons develop melanoma approximately one twentieth as frequently as white 
persons, and the prevalence in Hispanic persons is approximately one sixth of 
that in white persons. However, mortality rates are higher in African Americans 
and Hispanics, who are more likely to have acral melanoma and advanced 
disease at presentation (Cress and Holly 1997; Hu, Soza-Vento et al. 2006; Hu, 
Parmet et al. 2009; Kundu, Kamaria et al. 2010). 
 
1.5.6. Sex 
 In the western countries especially USA, the invasive melanoma has a higher 
female predilection from birth to age 39 years (1 in 370 women compared with 1 
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in 645 men). However, from age 40 years and older, melanoma in men 
predominates, occurring in 1 in 39 men compared with 1 in 58 women over a 
lifetime.
 
Worldwide, of the 160,000 new cases estimated to have occurred in 
2002, women were affected slightly more than men (male-to-female ratio, 
0.97:1). Conversely, of the estimated 41,000 worldwide deaths in 2002, more 
occurred in men than in women (male-to-female ratio 1.2:1) (Coelho and 
Hearing 2010; Coras, Landthaler et al. 2010; Rouhani, Pinheiro et al. 2010). The 
additional exposure of adolescents to unnaturally large amounts of UVA from 
UVA-rich sunlamps which produce visible tan sources is implicated in the 
increasing incidence of malignant melanomas disproportionately in young 
women (Coelho and Hearing 2010). 
 
1.5.7. Age 
Overall the mean age at melanoma diagnosis is 53 years; however, it is the most 
common cancer in women aged 25-29 years and is second only to breast cancer 
in women aged 30-34 years. The most striking differences in melanoma 
incidence and mortality occur in individuals older than 65 years, although modest 
differences in age-specific incidence and mortality are notable in persons older 
than 50 years (Geller, Miller et al. 2002).
 
 
Older individuals are both more likely to acquire and to die from melanoma; 
thus, elderly persons should be a primary target for secondary melanoma 
prevention, including early detection and screening (van der Meijden, van 
Bruchem-Visser et al. 2010).
 
Treatment options in elderly persons may also be 
limited because of comorbid medical conditions, an inability to tolerate adverse 
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medication effects or toxicity, the increased likelihood of drug interactions, and 
potential exclusion from clinical trials based on age criteria. 
1.5.5. Treatment 
The only effective and urgent treatment is complete surgical removal. No 
survival benefit has been demonstrated for adjuvant chemotherapy, nonspecific 
(passive) immunotherapy, radiation therapy, retinoid therapy, vitamin therapy, or 
biologic therapy (Veronesi, Adamus et al. 1982). Adjuvant interferon (IFN) alfa-
2b is the only adjuvant therapy approved by the US Food and Drug 
Administration for high-risk melanoma (currently defined as stages IIB, IIC, and 
III), which is associated with a 40-80% chance of relapse and death. Various 
experimental melanoma vaccines also show promise in the adjuvant setting 
(Kirkwood,  et al. 1996; Kirkwood, et al. 2000). 
 
 
Photography 1.5.5. Picture of Melanoma Skin Cancer, Photo © Skin Cancer Foundation 
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Photograph 1.5.6. Melanoma Skin Cancer, Photo © National Cancer Institute 
 
 
 
 
 
 
Photograph 1.5.7. ABCD rule illustration. On the left side from top to bottom: melanomas 
showing (A) Asymmetry, (B) a border that is uneven, ragged, or notched, (C) coloring of 
different shades of brown, black, or tan and (D) diameter that had changed in size. The normal 
moles on the right side do not have abnormal characteristics (no asymmetry, even border, even 
color, no change in diameter). en.wikipedia.org 
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Photograph 1.5.8. Malignant melanoma in skin biopsy with H&E stain. This case may represent 
superficial spreading melanoma. en.wikipedia.org 
 
 
 
 1.6. Oxidative stress and cancers 
 
Oxygen radicals are continuously generated within mammalian cells, this being a 
consequence of the use of oxygen in aerobic respiration. Superoxide is generated 
within the mitochondria and is sequentially reduced to hydrogen peroxide and 
hydroxyl radicals (Wiseman, 1996). The development of malignancy can be the 
result  of increasing in the ROS formation, In explaining this, most attention has 
been paid to direct oxidative damage to DNA by certain ROS, such as hydroxyl 
radical (OH
•
). However, increased levels of DNA base oxidation products such 
as the 8-OHdg (8-hydroxy-2´-deoxyguanosine) do not always lead to malignancy, 
although malignant tumours often show increased levels of DNA base oxidation. 
Oxidative stress constantly affects carcinoma cells in vivo and in vitro (Brown, 
2001).  Therefore the effects on P53 and cell proliferation, invasiveness and 
metastasis are the other results from of ROS. In chronic inflammation and 
developing cancers the function of ROS is very complicated and sometimes can 
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act as anti-inflammatory agents (Halliwell, 2007). One is oxidative damage to 
DNA that could lead to the mutational
 
events of initiation and progression. The 
other is interruption
 
of reactive oxygen-dependent cell signalling pathways 
controlling
 
gene expression that contribute to all stages of cancer, in
 
particular 
tumour promotion (Upham, 2001). 
 
Interestingly, malignant cells are more sensitive to damage by ROS generating 
agents due to the production of O(2)(-) and subsequent apoptosis, compared to 
normal cells and they are under intrinsic stress. The intrinsic oxidative stress in 
cancer cells was associated with the upregulation of SOD and catalase protein 
expression, as a likely mechanism to tolerate increased ROS stress. The increase 
in SOD and catalase expression is observed both in primary human leukaemia 
cells and in primary ovarian cancer cells. One of the certain agents generating 
reactive oxygen species (ROS) is 2-methoxyestradiol (2-ME). O (2) (-) is an 
important mediator of 2-ME-induced apoptosis. The increased oxidative stress in 
cancer cells forces these cells to rely more on antioxidant enzymes such as SOD 
for O(2)(-) elimination, thus making the malignant cells more vulnerable to SOD 
inhibition than normal cells (Hileman, 2004). Ultraviolet light induces free 
radical formation in skin, causing photoaging and cancer (Jurkiewicz, 1994). 
Oxygen radicals can induce a number of disruptive cellular processes, including 
lipid peroxidation, DNA cleavage, altered enzyme activity, polysaccharide 
polymerization, and cell death (Reynolds, 2007). 
An imbalance of prooxidants and antioxidants in the organism, is rapidly gaining 
recognition as a key phenomenon in chronic diseases (Ginter, 1996). Decreases 
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in antioxidant intake and high oxidative stress are linked with breast cancer risk 
(Sharhar, 2008). 
 The higher UVA radiation is a well-recognized generator of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) which play a key role in 
mediating its biological effects (Hoerter, 2008). Unbalancing of antioxidants 
percentage and oxidative products, induces oxidative damage the accumulation 
of which is considered as a risk factor in photoaging, photoimmunosuppression 
and photocarcinogenesis (Wood, 2006). That UVA contributes to inflammation 
and to the deleterious effects observed in photoaging, immunosuppression and 
skin cancer has been demonstrated (Mouret, 2006; Berneburg, 1999; Okada, 
2003). The production of ROS such as singlet oxygen (1O2) plays a key role in 
this pathway and direct evidence of its production in the skin has been obtained 
following UVA irradiation (Baier, 2007). In human keratinocytes, the high redox 
potential of O2 allows it to react with all major classes of biomolecules, the most 
important of them in protein oxidation (Pattison, 2006), lipid peroxidation 
(Minami, 2008) and DNA damage (Ravanat, 2001), and it may trigger the 
generation of other ROS. 
 
 
 1.7. UVA radiation 
 UV radiation is a toxic agent with genotoxic effects. It has been found to be 
associated with chromosome aberrations caused by breaks in the DNA strands. 
Cellular growth rate, cell viability, mitotic index, chromosomal instability and 
biomarkers of oxidative metabolism were analysed in lymphocyte cells from 
healthy adults with different Ala16Val MnSOD polymorphisms that produced 
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three genotypes: AA, VV and AV. They found a differential response to UV 
exposure in cultures of lymphocyte cells from Ala16Val genotype donors. In 
general, AA cell cultures presented higher viability and mitotic index and lower 
TBARS (antioxidant) levels than VV and AV cells for both the control and UV 
exposure groups. However, when they compared the DNA damage among the 
three genotypes, AA lymphocyte cells presented the highest damage from UV 
exposure. These data suggest that the Ala16Val polymorphism affects the 
response of cellular oxidative metabolism in different ways (Montagner, 2010). 
Intracellular and extracellular oxidative stress initiated by reactive oxygen 
species (ROS) advance skin aging, which is characterized by wrinkles and 
atypical pigmentation. Because UV enhances ROS generation in cells, skin aging 
is usually discussed in relation to UV exposure (Masaki, 2010). 
UV-induced damage is involved in the initiation of MM as melanocytes seem to 
be extremely susceptible to free radicals (Baldea, 2009; Wang, 2010). UVB 
(290–320 nm) exposure was thought to be responsible for non-melanoma skin 
cancer as it generates CPDs in skin cells which in turn can develop into 
cutaneous squamous cell or basal cell carcinomas (Mouret, 2006). By the 
increasing usage of UVA tanning beds and the parallel rise in the development of 
melanomas, the adverse effects of UVA exposure (320-400 nm) was also 
suggested (Mouret, 2006). Like UVB, UVA can cause non-melanoma skin 
cancers, but tumours take longer to develop and require much higher doses. 
UVA-induced skin cancers have been thought to derive from indirect damage to 
DNA caused primarily by the generation of reactive oxygen intermediates 
(Mouret, 2006).  
 101 
 
1.8. Comet assay 
One of the genetic endpoints to be presented in this dissertation is in the single 
cell gel electrophoresis or Comet Assay. The SCGE assay is a rapid and sensitive 
florescent microscopic method to examine DNA damage and repair at the 
individual cell level. 
Rydberg and Johanson described the technique for the first time (Ryberg, 1978). 
Östling and Johanson 1984 developed a microgel electrophoresis technique, 
commonly known as the Comet assay. 
The assay is an attractive test for measuring genotoxicity and investigating DNA 
repair, or monitoring humans/animals for exposure against environmental 
mutagenesis and chemical carcinogenesis. 
The comet assay has widespread applications in toxicology testing/human 
biomounitoring in vitro and in vivo (Anderson et al, 1998).  
Since the introduction of the alkaline comet assay in 1988 by Singh et al, a 
number of advances have greatly increased the flexibility and utility of this 
technique for detecting various forms of DNA damage, and DNA-DNA/DNA-
protein/DNA-drug cross linking) and DNA repair in virtually any eukaryotic cell 
( Anderson et al, 1998). 
 Two versions of the comet assay are currently in use, one introduced by Singh et 
al 1998, who used alkaline electrophoresis (pH > 13) in order to increase the 
sensitivity for analysing DNA damage (after treatment with H2O2 ) which is 
capable of detecting DNA single strand breaks (SSBs), and alkali labile sites in 
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individual cells. This version is known as the ―Single Cell Gel Electrophoresis 
(SCGE) technique‖, although for historical reasons many investigators refer to 
this method as the ―Comet assay‖ due to shape of the comet tail. 
Also Olive and co-workers developed versions of the neutral technique of 
Östling and Johanson, which also involved lysis in less alkali treatment (Olive, 
1989).   
 
1.9. Micronucleus assay 
 
The other endpoint is the micronucleus (MN) is an acentric chromosome 
fragment or whole chromosome that is left behind during mitotic cellular 
division and appears in the cytoplasm of interphase cells as a small additional 
nucleus (Kirsch-Volders, 2003). The formation of MN in dividing cells is the 
result of chromosome breakage due to unrepaired or disrepaired DNA lesions, or 
chromosome malsegregation due to mitotic malfunction (Photograph 1.9.1, 
1.9.2). These events may be induced by oxidative stress, exposure to clastogens 
or aneugens, genetic defects in the cell cycle checkpoint and/or DNA repair 
genes, as well as deficiencies in nutrients required as co-factors in DNA 
metabolism and chromosome segregation machinery (Fenech, 1999;Fenech, 
2005). All these events can cause the formation of MN through chromosomal 
rearrangements, altered gene expression or aneuploidy, effects associated with 
the chromosome instability phenotype often seen in cancer (Fenech, 2002;Fenech, 
2003) (Photographs 1.9.1, 1.9.2). The presence of an association between MN 
induction and cancer development is supported by a number of observations. The 
most substantiated include: the high frequency of MN in untreated cancer 
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patients and in subjects affected by cancer-prone congenital diseases, e.g. Bloom 
syndrome or ataxia telangiectasia (Fenech, 2002;Fenech, 1999), the presence of 
elevated MN frequencies in oral mucosa, used as a surrogate biomarker of cancer 
in clinical chemo-prevention trials(Van Schooten, 2002), the correlation between 
genotoxic MN-inducing agents and carcinogenicity, e.g. ionizing and ultraviolet 
radiation (Chang, et al.,1997;(Bettega, Calzolari et al. 2003) 
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Photograph 1.9.1. Micronuclei detected in binucleated cell. 
www.igcar.ernet.in/igc2004/sg/micronuc.htm 
  
 
Photograph 1.9.2.  Micronuclei detected in binucleated cell. www.igcar.ernet.in/igc2004/sg/micronuc.htm 
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1.10. Aim and objectives of the present studies 
 
The primary aim was to investigate the effect of oxidative stress and antioxidants 
on lymphocytes from patients with inflammatory bowel disease. Also the effect 
of UVA on cancerous and pre-cancerous states (malignant melanoma, suspected 
melanoma and colorectal cancer, polyposis coli patients). Lymphocytes from all 
diseases states were compared with those from healthy control individuals. Two 
genetic endpoints that were used were the Comet and micronucleus assays.                
 
 
 
 
 
 
                                  
 
 
 
 
                                   
 
 106 
 
 
 
 
 
                           CHAPTER TWO    
                              
 
                MATERIALS AND METHODS      
 
 
 
 
 
 
 
 
 
 
 
 107 
 
2. Materials and Methods 
2.1. Ethical approval studies for patients and healthy control individuals 
Whole blood was collected by myself with venepuncture from donors before 
each experiment. The donors were gastroenterology patients from two clinics, St. 
Luke’s Hospital and Bradford Royal Infirmary (BRI) in Bradford, West 
Yorkshire, UK. Healthy volunteers were recruited within the Division of 
Biomedical Sciences at the University of Bradford, West Yorkshire, UK. Ethical 
permission has been obtained from both the BRI Local Ethics Committee and the 
University of Bradford’s Sub-Committee for Ethics in Research involving 
Human Subjects. Controls were from the University of Bradford. Ethical 
permission was obtained from both the BRI Local Ethics Committee for the 
experiments (reference numbers, malignant melanoma; 04/QI202/132 and 
colorectal cancer; 04/Q1202/15) and the University of Bradford’s sub-committee 
of Research Ethics involving Human Subjects (reference number 0405/8). 
 
 
2.2. The Comet assay and micronucleus assay  
2.2.1. Comet assay 
 The single cell gel electrophoresis (SCGE) or Comet assay is a rapid and very 
sensitive fluorescent microscopic method to assess DNA damage and repair at 
the individual cell level (Tice, 2000).
 
Since the introduction of the alkaline 
(pH >13) Comet assay (Singh, 1988), the flexibility and efficacy of this 
technique for detecting various forms of DNA damage (e.g., single- and double-
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strand breaks, oxidative DNA base damage, and DNA-DNA/protein/DNA-drug 
cross-linking) and DNA repair have increased its use in virtually all eukaryotic 
cells (Tice, 2000). In the Comet assay, DNA migration is found to be a function 
of both size and the number of broken DNA ends. The length of the Comet tail 
increases initially with damage and then reaches a maximum size that depends on 
the electrophoretic conditions. Tail moment, a measure of tail length and the 
fraction of DNA in the Comet tail, was used as the arbitrary unit of assessment 
(Kumaravel, 2006;Anderson, 2003). The Comet assay was carried out as 
described by Tice et al. (2000) (Tice, 2000). In brief, ethanol flamed glass slides 
from BDH (Superfrost
TM
) were coated with 1% agarose. The cell suspension was 
mixed 1:1 with 1% low-melting point agarose (< 40°C) and applied to dry 
agarose-coated slides. After setting, this second layer was covered with a top 
layer of 0.5% low-melting point agarose. For each dose point two replicate slides 
were produced. The slides were immersed laterally in a container with cold 
lysing solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 10% DMSO, 1% 
Triton X-100, pH 10) and incubated at 4ºC overnight. After lysis, the slides were 
placed horizontally on the tray of an electrophoresis tank, filled with cold 
electrophoresis buffer (300 mM NaOH, 1 mM EDTA, pH <13), and incubated 
for 30 minutes at 4ºC in the dark to allow the unwinding of DNA and expression 
of the alkali labile damage. Electrophoresis was conducted at the same 
temperature for 30 minutes at 25 volts and an adjusted current of 300 mA (by 
raising or lowering the buffer level). After electrophoresis, the slides were 
removed from the tank and soaked three times each with neutralising buffer (400 
mM Tris, pH 7.5) for a period of five minutes each (Anderson, 2003; Tice, 2000).  
Cells were stained with 20 µg/ml ethidium bromide and examined using a 
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fluorescence microscope equipped with a monochrome CCD-camera. For each 
replicate slide, 25 cells were scored (50 cells in total, making 1000 observations 
per experimental point ( 20 patients, 20 controls) allowing a more than adequate 
statistical power to detect effects). A computerised image analysis system, 
Komet 4.0 (Kinetic Imaging, Liverpool, UK), was employed to measure the 
Comet parameters; the median Olive tail moment was then used for statistical 
analysis. All other chemical reagents were obtained from VWR International 
laboratories suppliers address in the UK.  
  
2.2.2. Lymphocyte isolation from peripheral blood 
 
 Blood was collected into heparin-coated tubes and diluted with 0.9% saline in a 
50:50 proportion. Then, this diluted blood was carefully loaded on top of 
Lymphoprep (Axis, Norway) in a ratio of 2:1 without mixing the two layers.  
The tubes were placed in a Mistral 3000 centrifuge at 800 g for 20 minutes at 
room temperature. After centrifugation, the cloudy, thin lymphocyte layer on top 
of the transparent Lymphoprep layer was transferred with a Pasteur pipette into 
universal tubes containing 0.9% saline. The tubes were centrifuged at 770 g for 
15 minutes at room temperature. The supernatant was removed and the 
lymphocytes were used for the experiments after resuspension within RPMI. 
Some of the lymphocytes were stored in liquid nitrogen for long-term 
experimentation. The pellet was resuspended in 1 ml of foetal bovine serum 
(FBS) with 10% DMSO in a 1.5-ml cryovial and lodged in liquid nitrogen 
vapour overnight, before final storage after complete insertion in the storage 
Dewar. 
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2.2.3. Questionnaire for patients and controls (as shown in appendix 1) 
A questionnaire was administered to each donor immediately after taking the 
blood sample. The completed questionnaire for the patient and control groups 
provided essential information about lifestyle, confounding factors and medical 
treatment or any other drug intake.  
 
2.2.4. Treatment 
The isolated lymphocytes were treated in two series of experiments. In the first 
one lymphocytes treated with different doses of Chaga extract, H2O2. Chaga 
mushroom extract was obtained from Fungi Perfecti’s Mycomedicinals, Chicago, 
USA. According to the manufacturer’s description, 30 drops of this alcohol-
based extract are equivalent to 1g of Chaga mushroom mycelium fruit bodies. In 
the second experiment the lymphocytes from patients and healthy individual 
controls treated with different doses of IQ and flavonoids (quercetin, epicatechin) 
and for third experiment with UVA (PUVA).  
 
2.2.5. Cell viability check 
Cell viability at the concentrations chosen for each experiment was checked after 
treatment before performing the Comet assay. Viability was determined by 
trypan blue exclusion (10 µl of 0.05% trypan blue was added to 10 µl of cell 
suspension) and the percentage of cells excluding the dye was estimated using a 
haemocytometer under the microscope. Only concentrations with viability over 
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80% were accepted to avoid artefactual results from cytotoxicity (Henderson, 
1998). 
 
2.2.6. Statistical analysis for the Comet assay 
 
Gaussian normality was violated for many of the scale variables as endorsed by 
the Kolmogorov-Smirnov test. Therefore, non-parametric test procedures were 
adopted wherever necessary, such as the Kruskal-Wallis (K-W) and the Mann-
Whitney (M-W) tests for independent samples. The unit of assessment was end 
individual sample when testing intra-subject differences in DNA damage; the 
Wilcoxon Signed Rank (WSR) Test was applied. For the binary response 
variables, Fisher's Exact (FE) Test was applied. Throughout the analyses, a 
significance level of 5% was used and unilateral alternative hypotheses preferred 
to bidirectional tests (wherever appropriate). Graphical evidence in support of 
findings was described in terms of medians and quartiles, and illustrated using 
Box Plots. Outliers and extreme values were defined in the conventional manner 
by the statistical package SPSS (Version 13 and 16).  
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2.3. The cytokinesis block micronucleus (CBMN) assay  
 
After collection, whole blood (500 µl) from each of the patients and healthy 
individuals was cultured on the same day as the collection in 25 cm
2 
culture 
flasks in 4.5 ml RPMI 1640 medium with L-glutamine (Gibco, Paisley, UK) 
supplemented with 15% heat inactivated foetal calf serum (Gibco, Paisley, UK), 
100 U/ml penicillin and 100 U/ml streptomycin (both from PAA Laboratory 
GmbH, Pasching, Austria) and 2% phytohaemaglutinin A 16 (PHA; Murex 
Biotech Ltd., Dartford, UK) to stimulate lymphocyte proliferation. Cultures were 
incubated for seventy two hours in a humidified incubator at 37°C and 5% CO2. 
From each sample (patients and controls) three culture flasks were prepared. 
Twenty four hours after starting the cultures one of the flasks from each set was 
exposed to UVA for 30 minutes at a mean sample surface intensity of 1.53  
0.01 mWcm
-2
. While the second flask of each set remained untreated, the culture 
in the third flask was treated with mitomycin C (MMC) 0.4 µM as a positive 
control. Cytochalasin B (Sigma-Aldrich, ST. Louise. MO) was added 44 h after 
starting the cultures at 6 µg/ml per culture. After 72 h, the cultures were 
centrifuged at 190x g for 8 minutes at room temperature and cells were treated 
with cold hypotonic KCl solution (110 mM) at 4°C for 15 min. After a 
centrifugation at 190x g for 8 min at room temperature, cells were fixed with 
fresh Carnoy’s solution (3:1 methanol: acetic acid) followed by three drops of 
37% formaldehyde to each preparation. Fixation was repeated twice without 
adding formaldehyde. The fixed cells were incubated over night in the 
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refrigerator and then spread onto dry glass slides. Two slides per culture were 
prepared, dried overnight and stained with filtered 5% Giemsa (Merck, 
Darmstadt, Germany) in pH 6.5 Soerensen buffer. All chemical reagents not 
specified otherwise were obtained from VWR, UK.  
 
Figure 2.2.1. A schematic figure of CBPI. Mutat Res., 2003 
 
The slides were evaluated for quality, then mounted with cover-slips and coded. 
The slides were scored according to the criteria defined by Fenech and 
colleagues (Fenech, 2003). Micronuclei (MN) were evaluated in 1000 
binucleated lymphocytes BiMN per treatment. Additionally, nuclear bridges 
(BiNPBs) and nuclear buds (BiBuds) were assessed in binucleated cells as well 
as micronuclei in mononucleated cells (MonoMN). The cytokinesis-block 
proliferation index (CBPI) was calculated from a total of 1000 mononucleated, 
binucleated and multinucleated cells per treatment. The CBPI is defined as: CBPI 
= [(number mononucleated cells + (2 * number binucleated cells) + (3 * number 
multinucleated cells) / total number of cells] (Kirsch-Volders, 2003).  
 
2.3.1. Statistical analysis for the CBMI 
 
For the CBMN assay, the numbers of MonoMN and BiMN, nuclear buds, 
nucleoplasmic bridges, CBPI and percentage of binucleated cells were used as 
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dependent variables. The different donors were considered as independent 
variables. The post-hoc analysis Fisher LSD test was used to determine the 
significant differences between group means. The level of statistical significance 
was set at 5% (p < 0.05). The statistical package STATISTICA 6.0 (IL, USA) 
was employed. 
 
Figure 2.2.2. CBPI & Fish. The cytokinesis-block micronucleus (CBMN) assay has emerged as 
one of the preferred methods for assessing chromosome damage. Micronuclei (MN) are small, 
extranuclear bodies that are formed in mitosis from acentric chromosomal fragments or 
chromosomes that are not included in each daughter nucleus. Thus, MN contain either 
chromosomal fragments or whole chromosomes. The CBMN assay, together with a fluorescence 
in situ hybridization (FISH) technique Mutat Res., 2003. 
 
 
 
                                                     
 115 
                                          
 
                                             
 
 
 
                                        
 
 
 
                                       CHAPTER THREE 
            INFLAMMATORY BOWEL DISEASE 
                                        AND 
                          CHAGA MUSHROOM  
                       (INNONOTOS OBLIQUUS) 
 
 
 
 
 
 116 
 
 
 
3. Introduction 
 
In this chapter lymphocytes from patients with IBD were exposed to H2O2 to 
induce oxidative stress and treated with chaga mushroom extract. They were 
compared to similarly exposed lymphocytes from healthy control individuals. 
 
 
3.1. Chaga mushroom 
Medicinal mushrooms, such as Chaga ―birch mushroom‖ which grows in 
northern regions on birch trees, have been found to inhibit the effect of 
carcinogens by exhibiting antioxidant properties, especially towards cancers of 
the stomach, oesophagus and lungs (Park et al., 2005).  Chaga (Inonotus obliquus) 
is a polypore that is a fungus with pores instead of gills. It is a fungal parasite and 
is medicine herbal supplement and is claimed to have beneficial properties for 
human health. The antioxidant effects of the mushroom protect cell components 
against free radicals. It has been shown in human lymphocytes in the Comet 
assay that Chaga mushroom extract treatment affords cellular protection against 
endogenous DNA damage produced by H2O2 (Park, 2005). 
The Chaga mushroom is a fungal parasite, which is claimed to have natural 
beneficial properties for human health such as anti-bacterial, anti-allergic, anti-
inflammatory and                                                                                                       
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antioxidant activities protecting cell components against free radicals (Naba, 
1994; Chen, 2010). The Chaga mushroom extract has also been shown to prevent 
the inhibition of GJIC, a model system of gap junctional intercellular 
communication (GJIC) in WB-F344 normal rat liver epithelial cells, through the 
inactivation of ERK1/2 and P38 MAP kinases (Park, 2006). In addition to the 
three known lanostane-type triterpenoids, inotodiol, trametenolic acid and 
lanosterol, two new compounds, called inonotsuoxide A and B, were isolated 
from the sclerotia of Inonotus obliquus (Nakata, 2007). It has been shown that 
the former three compounds have inhibitory effects on the Epstein-Barr virus 
early antigen (EBV-EA) activation induced by 12-O-tetracanoylphorbol-13-
acetate (TPA) and could therefore be a potential natural source of cancer 
preventive medicine (Nakata, 2007). The anti-cancer effect of Chaga endo-
polysaccharides is not directly tumorcidal but rather immuno-stimulating (Kim, 
2006). An endo-polysaccharide acting as a specific activator of B-cells and 
macrophages was extracted from the mycelia of Inonotus obliquus (Chaga 
mushroom). Although, the in vivo anti-cancer effects and the chemical structure 
of this particular endo-polysaccharide were unknown for quite some time, the 
purified endo-polysaccharide, however, showed in a more recent study immuno-
stimulating rather than tumorcidal activities in vitro as well as in vivo for both 
aqueous and ethanol extracts against various types of tumour cells (Youn, 2008; 
Youn, 2009 ;Mazurkiewicz, 2010). 3,4-dihydroxybenzalacetone (DBL) and 
sclerotia are the polyphenol derived from the medicinal fungi Chaga (Zheng, 
Zhang et al. 2009). Because most genes involved in inflammation, antiapoptosis, 
and cell proliferation are regulated by the transcription factor nuclear factor-
kappaB (NF-kappaB), it was postulated that DBL activity is mediated via 
 118 
modulation of the NF-kappaB activation pathway. The effects of DBL were 
investigated on NF-kappaB activation by the electrophoretic mobility shift assay 
and on NF-kappaB-regulated gene expression by Western blot analysis. The 
results indicated that DBL inhibits NF-kappaB activation and NF-kappaB-
regulated gene expression, which may explain the ability of DBL to enhance 
apoptosis and inhibit invasion (Sung, 2008).  
Four extracts from the fungus were evaluated for antioxidant activity against the 
1,1-diphenyl-2-picrylhydrazyl (DPPH), superoxide, and peroxyl radicals. The 
polyphenolic extract had a strong antioxidant activity, and the extract containing 
triterpenoids and steroids presented a relatively strong antioxidant effect. The 
polysaccharide extract, however, was inactive. The protective effects of these 
four extracts were assessed against hydrogen peroxide-induced oxidative stress 
using a human keratinocyte cell line, HaCaT. The results showed that the 
polyphenolic extract protected these cells against hydrogen peroxide-induced 
oxidative stress. The results indicated that Inonotus obliquus has the capacity to 
scavenge free radicals at concentrations higher than 5µg/ml and that the 
polyphenolic extract can protect cells against oxidative stress (Cui, 2005; 
Nakajima, 2009).  
Phenolic compounds produced by I. obliquus in the control medium consisted of 
melanins, flavonoids, polyphenols and small phenolics. Their accumulation was 
affected by adding H2O2 to the medium, where increased levels of total 
intracellular phenols (TIP) and melanins, but less total extracellular phenol (TEP) 
occurred. Simultaneous exposure to H2O2 and arbutin resulted in a further 
increase in TIP production and reduced accumulation of TEP. Both TIP and TEP 
obtained at different culture ages and media were active in scavenging 
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superoxide anion and DPPH radicals. Therefore, production of phenolic 
compounds by I. obliquus is enhanced by imposing oxidative stress, which might 
allow it to be exploited as a reliable source of pharmaceutically important 
phenolic compounds (Zheng, 2008). 
 
In the present study, we have investigated DNA damage using the Comet assay 
in human lymphocytes from patients with IBD compared with those from healthy 
control individuals. Cells have been treated in vitro with H2O2 in order to induce 
oxidative stress and also treated simultaneously with Chaga extract to determine 
if this can reduce the damage through its anti-oxidative properties. 
 
3.2. Material and methods  
The materials and methods used in this study have been described in section 2.1.  
 
3.2.1. Treatment 
Chaga mushroom extract was obtained from Fungi Perfecti’s Mycomedicinals, 
Chicago, USA. According to the manufacturer’s description, 30 drops of this 
alcohol-based extract are equivalent to 1g of Chaga mushroom mycelium fruit 
bodies. The purchased extract was further diluted in water to yield concentrations 
of 50, 100 and 500 µg of equivalent mycelium fruit body mass per millilitre. 
Isolated lymphocytes from 20 IBD patients were treated at first for 30 minutes at 
37ºC with different doses of Chaga extract (0, 50, 100 and 500 µg/ml) and then 
for an additional 30 minutes with H2O2 (50 µg/ml) added to the cell suspension. 
Lymphocytes which were collected from 20 healthy individuals were used as 
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control samples, and treated exactly as those from patients under the same 
conditions. After incubation, the treated lymphocytes were centrifuged at 900 g 
for five minutes. For DNA damage studies, 900 µl of the supernatant were 
removed. 
 
 
 
 
 
3.2.2. Statistical analysis 
 
The statistical methods that have been applied, described in section 2.1.1. 50 
cells were analyzed for individuals making a total of 1000 observations per 
experimental group and ensuring high statistical power throughout the study. 
However, data were analysed with the individuals as the unit of assessment. 
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3.3. Results 
 
3.3.1. Patient versus control group 
As shown in Figure 3.3.1, there was a significant difference in basic DNA 
damage within lymphocytes of IBD patients by comparing them with healthy 
control individuals controls (M-W, p < 0.001) before in vitro treatment The 
patient (study group) and the control groups showed increases in DNA damage 
from H2O2 alone (p < 0.001).  When the dose levels of Chaga extract were 
increased in successive steps, the observed damage was reduced towards the 
initial base level in both the patient and the control groups. Chaga mushroom 
extract gave an overall 54.9% reduction (p < 0.001) of DNA damage within the 
patient group and a 34.9% reduction (p < 0.001) within the control group. The 
level of induced damage from H2O2 in the IBD group was statistically 
significantly greater than that of the control group (p < 0.001), even with 
reduction of the damage by Chaga. The minimum in vitro dose of Chaga extract, 
at which the effect of H2O2 was neutralised, was determined as 10µg/ml for the 
control group and 50 µg/ml for the patient group (Figure 3.3.1). 
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Figure 3.3.1. IBD patient group (n = 20) and control group (n = 20) after in vitro 
treatment with H2O2 (50 μg/ml) and supplementation with ethanolic Chaga 
extract at different dose levels, showing median levels of DNA damage and 75% 
quartiles. The  and  symbols followed by a number indicate individual outliers 
with the respective patient number (Kolmogorov-Smirnov test, p < 0.001). The 
number of individuals in study and control groups is 20 each. 
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3.3.2. Differences in IBD sub-groups 
As shown in Figure 3.3.2, there was less damage in the UC (n = 8) patient group 
than in the CD (n = 8) group, which was significantly different (p < 0.001) when 
compared with the combined patient groups, which also included the 
indeterminate group where it was difficult to differentiate into UC or CD (n = 4) 
(Figure 3.3.2). 
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Figure 3.3.2. DNA damage within three IBD subgroups: the first two were 
diagnosed with Crohn’s disease (n = 8) and Ulcerative colitis (n = 8). The third 
group was an indeterminate subgroup (n = 4). The  and  symbols followed by a 
number indicate individual outliers with the respective patient number (Kruskal-
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Wallis (K-W) test, p < 0.001). The number of patients in the UC and CD is 8 
each and the indeterminate is 4. 
 
3.3.3. Confounding factors: 
a) Ethnicity, age, gender, smoking and drinking habits 
As shown in figures 3.3.3-3.3.6 there were small differences of median levels of 
DNA damage in Caucasians (n = 25) and Asians (n = 15) (Figure 3.3.6) as well 
as in males and females (Figure 3.3.3). However, these differences were not 
found to be statistically significant (M-W, p = 0.118); neither was there a 
statistically significant difference in the age distributions between patient (mean 
age = 40.20 years ± SD 11.62) and control (mean age = 32.35 years ± SD 9.00) 
groups. No major differences were seen due to smoking (Figure 3.3.4) and/or 
drinking habits (Figure 3.3.5). 
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Figure 3.3.3. DNA damage in patients and controls relating to gender:  male (n = 
19) and female (n = 21). The  and  symbols followed by a number indicate 
individual outliers with the respective patient number (Kruskal-Wallis (K-W) 
test). 
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Figure 3.3.4. DNA damage in patients and controls relating to smoking: active 
smokers (n = 19), ex-smokers (n = 2) and non smokers (n = 19). The  and  
symbols followed by a number indicate individual outliers with the respective 
patient number (Kruskal-Wallis (K-W) test). 
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Figure 3.3.5. DNA damage inpatients and controls relating to alcohol intake: non 
alcoholic (n = 26), moderate (n = 12) and severe (n = 4). The  and  symbols 
followed by a number indicate individual outliers with the respective patient 
number (Kruskal-Wallis (K-W) test). 
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Figure 3.3.6. DNA damage in patients and controls relating to ethnicity: 
European (n = 27) and Asian (n = 13). The  and  symbols followed by a 
number indicate individual outliers with the respective patient number (Kruskal-
Wallis (K-W) test). 
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b) Previous medication in the IBD group as a confounding factor 
As shown in figure 3.3.7 patients had been treated with a range of drugs for IBD, 
namely, methotrexate azathioprine, mesalazine and pantasa, asacol, prednisolone, 
mercaptopurine alone or in combination prior to taking part in the study 
[balsalazide & calcium (n = 2); azathioprine & pentasa, azathioprine & 
mesalazine, mercaptopurine & balsalazide (n = 10); asacol (n = 4); pentasa & 
prednisolone, prednisolone & mesalazine (n = 3); methotrexate & mesalazine (n 
= 1)]. Within the treatment groups, there appeared to be differences but because 
of small sample sizes they were not significant (Figure 3.3.7).  
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Figure 3.3.7. 
1. Methotrexate, azathioprine, mesalazine and pantasa, asacol, 
prednisolone, mercaptopurine alone or in combination prior to 
taking part in the study balsalazide & calcium (n = 2) 
2.  Azathioprine & pentasa, azathioprine & mesalazine, 
mercaptopurine & balsalazide (n = 10)  
3. Asacol (n = 4) 
4. Pentasa & prednisolone, prednisolone & mesalazine (n = 3) 
5.  Methotrexate & mesalazine (n = 1)] 
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3.4. Discussion 
 
The Chaga mushroom is a wood-rotting fungus used as a folk medicine in Russia 
and East-European countries to treat tuberculosis, gastritis and cancers. In some 
Asian countries, a large number of herbal and mushroom extracts has been used 
traditionally for treatment of inflammatory disease. These mushrooms, such as 
Ganoderma lucidum (Reishi), Lentinus edodes (Shiitake), Grifola frondosa 
(Maitake), Hericium erinaceum (Yamabushitake) and Inonotus obliquus (Chaga) 
have been collected throughout China, Korea and Japan, but they are almost 
unknown as treatment options for patients in the West. The pharmacological 
importance of these mushrooms is very high in the Far East as a traditional 
medicine in treating various diseases (Lee, 2007 ;Saar, 1991). For the Chaga 
mushroom, it has been ascribed with a number of biologically active 
polysaccharides and immuno-stimulatory properties, which seem to protect cells 
also against free radicals (Allgayer, 1991; Kim, 2007;Lee, 2007; Nakata, 2007). 
It has as well been recognised that oxidative stress is universally accepted as an 
important factor in the pathogenesis of IBD (Allgayer, 1991).  
Inhibition of iNOS and COX-2 expression via the down-regulation of NF-kappa 
B binding activity may explain the anti-inflammatory and anti-nociceptive 
properties of a methanol extract from Inonotus obliquus (Park, 2005; Van, 2009). 
A previous study using the Comet assay in human lymphocytes after in vitro 
treatment with Chaga mushroom extract has shown cellular protection against 
endogenous DNA damage produced by H2O2 (Park, 2004; Zheng, 2009). 
Inonotus obliquus supplementation in the form of an ethanol extract to human 
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lymphocytes and macrophages in vitro was able to markedly inhibit H2O2-
induced oxidative damage to cellular DNA (Kim, 2007;Park, 2004). 
In the present in vitro study, for the first time a reduction of induced DNA 
damage is reported in H2O2-treated lymphocytes obtained from IBD patients and 
healthy volunteers after treatment with an ethanolic extract of the Chaga 
mushroom (Figure 3.3.1). This protective effect has been shown to be 
statistically significant. H2O2 alone is known to cause destabilisation of the DNA 
structure by breaking DNA strands in a dose-dependent manner (Limoli, 2003). 
An in vitro treatment of isolated lymphocytes from IBD patients and healthy 
volunteers with 50 µg/ml H2O2 created a maximum of oxidative stress but left 
the cells still viable so that cytotoxicity did not confound effects (Henderson, 
1998). This damage significantly levelled off with increasing doses of the Chaga 
extract.  
 
Interestingly, also in the present study lymphocytes from CD patients appeared to 
have a greater level of basic DNA damage than those from UC patients when 
compared to the whole patient group (p < 0.001), suggesting that there may be 
more oxidative stress involved with Crohn’s disease (Figure 3.3.2). This is a very 
important new finding using the Comet assay in peripheral lymphocytes serving 
as surrogate cells for colonic mucosa cells. It seems that a misbalanced 
production of pro-inflammatory and anti-inflammatory cytokines is characteristic 
of IBD and severely affects the immune homeostasis in peripheral blood cells, 
even more in CD than in UC patients (Sventoraityte, 2008). Increased free 
radical production as well as a simultaneously reduced antioxidative potential 
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(Loguercio, 2003;Koch, 2000) contribute to the DNA damage not only in situ but 
also in peripheral lymphocytes.  
 
In our study, we found no differences for the level of DNA damage between 
patient and control groups regarding confounding effects such as smoking and 
drinking alcohol. However, it is known that smoking increases oxidative DNA 
damage by approximately 50% (Loft, 1992). For smokers, the higher 8-OHdG 
excretion might be related to a higher rate of
 
metabolism with increased 
availability of reactive oxygen species (Chen, 2007).
 
The apparent 7-fold 
individual variation in oxidative DNA damage
 
carries implications regarding 
ageing and the risk
 
of cancer and other degenerative diseases (Loft, 1992; 
Takeuchi, 1993; Cooke, 2003). Also when the effects of gender and ethnicity 
were examined, both showed trends towards being more sensitive to induced 
DNA damage for females (n = 24) compared to males (n = 16), and for the 
Caucasian group (n = 25) compared to the Asian group (n = 15), but neither was 
significant. Differences in life style, diet and possibly genetic background, e.g. 
different isoforms of metabolising enzymes, might contribute to such an 
increased trend without reaching significance. Nevertheless, Baypajee and 
colleagues found significantly higher basal level of DNA damage between males 
and females in the normal healthy South Indian population where males showed 
higher levels of damage levels than females (Bajpayee, 2002). Furthermore, as 
IBD patients who volunteered for this study had been on medication against 
bowel inflammation, which was also considered a confounding factor possibly 
contributing to the background DNA damage. The statistical significance in the 
difference of baseline values between the control and the study group might 
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partly be explained by such medication causing increased damage as well as 
increased inflammatory responses in the patients. 
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4. Introduction 
 
In this chapter lymphocytes from patients with IBD were exposed to a 
heterocyclic amine and flavonoids and compared to lymphocytes from healthy 
control individuals also exposed to these compounds.  
 
 
4.1. Heterocyclic amines and flavonoids 
 
The generation of DNA damage by environmental, medical or life style factors 
is considered to be an important initial event in carcinogenesis. Despite various 
cellular mechanisms to counteract these detrimental events the sheer number of 
potentially carcinogenic compounds leading to oxidative stress can negatively 
affect the cells’ DNA integrity. 
 
4.2. Heterocyclic Amines 
A very important family of promutagenic/carcinogenic chemicals, the 
heterocyclic amines (HCA), is widely produced when cooking food, especially 
during the pyrolysis of creatinine, amino acids
 
and proteins (Schut, 1999). Major 
subclasses of HCA found in the human
 
diet comprise of aminoimidazoazaarenes 
(AIA), 2-amino-3-methylimidazo[4,5-f]quinoline
 
(IQ), 2-amino-3,4-
dimethylimidazo[4,5-f]quinoline (MeIQ), 2-amino-3,8-dimethylimidazo[4,5-
f]quinoxaline
 
(MeIQx), 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline 
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(DiMeIQx)
 
and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) 
(Schut, 1999; Sutandyo, 2010). There is increasing evidence for the involvement 
of HCA as pyrolysis products of high protein diets
 
in the aetiology of human 
cancer {Adamson, 1996; Bogen, 1994; Metry, 2010), which has stimulated
 
strong efforts to identify exogenous and endogenous factors
 
that modify health 
risks caused by HCA. More than 600
 
individual compounds and complex dietary 
mixtures have been
 
studied for protective effects towards HCA (Schwab, 2000) 
and numerous articles have been published regarding mammalian enzymes
 
involved in the bioactivation and detoxification of these compounds (Eisenbrand, 
1993; Haza, 2010).  
In addition to the formation of DNA adducts as a major causal factor in the 
carcinogenesis of HCA, oxidative stress plays a crucial role in further damaging 
the DNA (Murata, 1999).  
 
4.3. Flavonoids 
Dietary flavonoids acting as antioxidants (Rice-Evans, 2001) have been 
identified to be capable of counteracting these adverse oxidative effects. 
Flavonoids are classified as polyphenolic compounds that are ubiquitous in 
nature and categorised according to their chemical structure into flavonols, 
flavones, flavanones, isoflavones, catechins, anthocyanidins and chalcones. So 
far, thousands of flavonoids have been found and identified in plants showing 
antioxidant qualities (Rice-Evans, 2001; Mochizuki, 2010). The antioxidant 
potency of several widespread dietary
 
flavonoids showed a dose-dependent 
reduction of induced oxidative
 
DNA damage in vitro, highlighting an even 
higher protective effect than vitamin C (Noroozi, 1998).  It has also been shown 
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that flavonoids intake can lower the mortality rate caused by coronary heart 
disease (Kaur, 2007). 
 
Ulcerative colitis and Crohn's disease are inflammatory disorders of the 
gastrointestinal tract, which are unevenly distributed within the populations 
throughout the world. Although the exact cause of IBD remains unknown, the 
epidemiology of IBD has provided an insight into the pathogenesis of the 
disease by examining geographic, ethnic and other IBD risk factors (genetic, 
environmental, etc.) as well as their natural history (Danese, 2006). Interestingly, 
reactive oxygen species (ROS) are produced in abnormally high levels in cells 
from IBD patients (Rezaie, 2007) leading to oxidative stress and thus to DNA 
damage due to an imbalance between innate and exogenous antioxidants and 
ROS (Hemnani, 1998; Soffler, 2007) (Figure 4.3.1).  
Oxidative stress has been linked to cancer, aging, atherosclerosis, ischaemic 
injury, inflammation and neurodegenerative diseases (Davies, 1995; Tudek, 
2010).  
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Figure 4.3.1. Schematic illustrating the proposed mechanism of how chronic inflammation may 
induce microsatellite instability in Ulcerative colitis. Among the factors released by 
inflammatory cells in Ulcerative colitis are proinflammatory cytokines, ROS, and NO. MSI 
(microsatellite instability), AAG (alkyladenine DNA glycosylase), APE1 (apurinic/apyrimidinic 
endonuclease 1)  Hofseth et al 2003. 
 
 
Medically, IBD is characterised by the infiltration of CD4+ T-lymphocytes and 
other mononuclear cells into inflamed mucosal regions (Seegert, 2001; Cai, 
2010). During this process interleukin 16 (IL-16) exerts a strong chemo-
attractant activity towards CD4+ cells. Moreover, IL-16 activates the expression 
and production of pro-inflammatory cytokines such as IL-1 beta, IL-6, IL-15 and 
tumour necrosis factor alpha (TNF-alpha) in human monocytes (Seegert, 2001). 
The cytokine TNF-alpha plays a crucial role in the pathogenesis of IBD (Spoettl, 
2007).  To inhibit TNF-alpha activity biotechnologically manufactured agents 
such as the chimeric monoclonal anti-TNF antibody (infliximab), a human 
monoclonal anti-TNF antibody (CDP571) and a recombinant TNF receptor 
fusion protein (etanercept) have been used (Ardizzone, 2005; van Assche, 2010). 
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Important insights have also been gained into the function of ―caspase-activating 
and recruitment domain-15‖ (CARD15)/NOD2, the first cloned susceptibility 
gene for CD (Rogler, 2004; Rigoli, 2008). An inflammatory reaction of the 
intestinal mucosa as a response of the innate immune system may be essential 
for the maintenance of gut homeostasis (Rogler, 2004). CD may therefore be 
seen as a defective immune response, no longer only as hyper-responsiveness of 
the mucosal immune system. Data on CARD15/NOD2 expression suggest that 
macrophages and epithelial cells could be the site of a primary pathophysiologic 
defect, and T-cell activation might just be a secondary effect inducing chronic 
inflammation, perhaps as a backup mechanism to a defective innate immunity 
(Rogler, 2004; Rigoli, 2008). Nevertheless, additional "innate" pathways by 
which commensal and pathogenic bacteria are able to directly interact with cells 
of the intestinal mucosa exist (e.g., toll-like receptors).  
 
In this present study, we used the Comet assay, as a fast and reliable method that 
is able to detect genotoxicity in virtually any mammalian cell type without the 
requirement for cell culture (Moller, 2006), in human lymphocytes from 20 IBD 
patients and 20 healthy individuals. The antioxidant effect of the flavonoids 
quercetin and epicatechin (Sachse, 2002; Haza, 2010) was tested in the presence 
of an exogenous oxidative insult (H2O2) to show that these two flavonoids are 
able to reliably protect cells against the damaging effects of reactive oxygen 
species, even in the context of a disease like IBD where levels of ROS are 
already highly increased. 
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4.3. Materials and methods 
The materials and methods used in this study have been described in section 2.1.  
 
4.3.1. Treatment 
Isolated lymphocytes from 20 new IBD patients and 20 controls were treated for 
30 minutes at 37 ºC either with different doses of quercetin (0, 50, 100, and 200 
µg/ml) in the presence of hydrogen peroxide (50 µg/ml) or with different doses 
of epicatechin (0, 25, 50, 100 µg/ml) together with IQ (50 µg/ml) (i.e. 10 
patients in each patient group) . Lymphocytes from healthy individuals served as 
a control group. After incubation, the cells were pelleted (5 minutes at 900 g) 
and resuspended in 100 µl of the remaining supernatant. For DNA damage 
studies, the cell suspension was mixed with the same volume of 1% low melting 
point agarose for the Comet assay. 
 
4.3.2. Statistical analysis 
The statistical methods have been applied, described in section 2.2.1. 50 cells 
were analyzed for individuals making in a total 500 observations per 
experimental IBD group and 1000 for the control group and everything high 
statistical power throughout the study.  
 
4.4. Results 
4.4.1. Patient versus control group  
As shown in Figures 4.4.1 and 4.4.2, there was a significant difference in basic 
DNA damage within lymphocytes of IBD patients when comparing them with 
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healthy individual controls (2.5- fold in the groups  treated with H2O2 and 
quercetin and 5.2-fold in the groups treated with IQ and epicatechin )  (M-W, p < 
0.001) before in vitro treatment.  
The study groups as well as the control groups showed significant increases in 
DNA damage induced by H2O2 (study group = 2.1-fold and control group = 3.2-
fold) (p < 0.001) and IQ (study group = 2.0-fold and control group = 3.6-fold) (p 
< 0.001). The induced damage caused by the in vitro treatment with H2O2 or IQ 
decreased significantly in both groups when co-treated with the flavonoids 
quercetin or epicatechin, respectively (Figures 4.4.1 and 4.4.2).  
Flavonoids supplementation at the highest concentration (250 μM quercetin or 
100 μM epichatechin) caused an overall significant reduction of the induced 
DNA damage within the patient group and the control groups. This resulted in a 
48.6% (p < 0.001) reduction of H2O2 induced DNA damage and a 43% reduction 
of IQ induced DNA damage within the patient groups. For both control groups, 
reductions in DNA damage of 35.2% and 57.1%, respectively, were observed 
(both, p < 0.001) (Figures 4.4.1 and 4.4.2). As expected, the two different 
control groups showed the same basic DNA damage (M-W, p < 0.174. t-test p < 
0.134). 
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Figure 4.4.1. IBD patient group and control group (n = 10 each) after in vitro 
treatment with H2O2 (50 μg/ml) and supplementation with the flavonoid 
quercetin at different concentration levels, showing median levels of DNA 
damage and 75% quartiles. The  and  symbols followed by a number indicate 
individual outliers with the respective patient number (Kolmogorov-Smirnov test, 
p < 0.001).  
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Figure 4.4.2. IBD patient group and control group (n = 10 each) after in vitro 
treatment with IQ (50 μg/ml) and supplementation with the flavonoid epicatechin 
at different concentration levels, showing median levels of DNA damage and 
75% quartiles. The  and  symbols followed by a number indicate individual 
outliers with the respective patient number (Kolmogorov-Smirnov test, p < 
0.001). 
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4.4.2. Differences in IBD sub-groups  
As shown in Figures 4.4.1 and 4.4.2 there was less baseline damage in the UC 
patient group (n = 4) than in the CD group (n = 4) each being significantly 
different (p < 0.001) (2.0-fold in the study group which was treated with H2O2 
and quercetin and 3.8-fold in study group treated with IQ and epicatechin) when 
compared with the combined patient groups, which also included the 
indeterminate group where it was difficult to differentiate into UC or CD (n = 2). 
Also there was less induced DNA damage in the study group treated with H2O2 
and quercetin compared with the study group treated with IQ and epicatechin 
although the patients were selected randomly (Figures 4.4.3 and 4.4.4). There 
was less induced damage of DNA in the newly selected lymphocytes from UC 
patients compared to CD patients in both series of experiments (H2O2 with 
quercetin and IQ with epicatechin (p < 0.001) (Figures 4.4.3 and 4.4.4). 
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 Figure 4.4.3. DNA damage within three IBD subgroups after in vitro treatment 
with H2O2 (50μg/ml) and supplementation with the flavonoid quercetin at 
different concentration levels: the first two were diagnosed with Crohn’s disease 
(n = 4) and Ulcerative colitis (n = 4). The third group was an indeterminate 
subgroup (n = 2). The  and  number (Kruskal-Wallis (K-W) test, p < 0.001).  * 
(P < 0.01) and ** (P < 0.001) .  
 147 
IBD sub groups
1ntermediateCrohn's diseaseUlcerative colitis
O
li
v
e
 T
a
il
 M
o
m
e
n
t
50
40
30
20
10
0
IQ 50µM+ Epi 100µM
IQ 50µM+ Epi 50µM
IQ 50µM+ Epi 25µM
IQ 50µM+ Epi 0µM
IQ 0µM+Epi 0µM
 
Figure 4.4.4. DNA damage within three IBD subgroups after in vitro treatment 
with IQ (50 μg/ml) and supplementation with the flavonoid epicatechin at 
different concentration levels: the first two were diagnosed with Crohn’s disease 
(n = 4) and Ulcerative colitis (n = 4). The third group was an indeterminate 
subgroup (n = 2).   * (P < 0.01) and **  (P < 0.001). (Kruskal-Wallis (K-W) test, 
p < 0.001).  
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4.4.3. Confounding factors: 
a) Ethnicity, age, gender, smoking and drinking habits 
As shown in figures 4.5-4.13 there were small differences of median levels of 
DNA damage in Caucasians (n = 13) and Asians (n = 7) (Figures 4.4.11, 4.4.12) 
as well as in males and females (Figures 4.4.7, 4.4.8). However, these differences 
were not found to be statistically significant (M-W, p = 0.170); neither was there 
a statistically significant difference in the age distributions between patient 
(mean age = 42.40 years ± SD 11.62) and control (mean age = 28.9 years ± SD 
9.00) groups. No major differences were seen due to smoking (Figures 4.4.9, 
4.4.10) and/or drinking habits (Figures 4.4.5, 4.4.6). 
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Figure4.4.5. DNA damage in patients and controls (all subjects n = 20, 10 each 
group) relating to alcohol intake: non alcoholic (n = 7), moderate alcoholic (n = 7) 
and severe alcoholic (n = 6) groups after in vitro treatment with H2O2 (50 μg/ml) 
and supplementation with the flavonoid quercetin at different concentration 
levels. The   and  symbols followed by a number indicate individual outliers 
with the respective patient number (Kruskal-Wallis (K-W) test). 
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  Figure 4.4.6. DNA damage in patients and controls (all subjects n = 20, 10 each 
group)relating  to alcohol intake: non alcoholic (n = 7), moderate alcoholic (n = 7) 
and severe alcoholic (n = 6) groups after in vitro treatment with IQ (50 μg/ml) 
and supplementation with the flavonoid epicatechin at different concentration 
levels. The   and  symbols followed by a number indicate individual outliers 
with the respective patient number (Kruskal-Wallis (K-W) test).  
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Figure 4.4.7. DNA damage in patients and controls (all subjects n = 20, 10 each 
group) regarding to gender: male (n = 11) and female (n = 9) groups, after in 
vitro treatment with H2O2 (50 μg/ml) and supplementation with the flavonoid 
quercetin at different concentration levels.  The   symbol followed by a number 
indicate individual outliers with the respective patient number (Kruskal-Wallis 
(K-W) test).  
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Figure 4.4.8. DNA damage in patients and controls (all subjects n = 20, 10 each 
group) relating to gender: male (n = 11) and female (n = 9) groups, after in vitro 
treatment with IQ (50 μg/ml) and supplementation with the flavonoid epicatechin 
at different concentration levels.  The   symbol followed by a number indicate 
individual outliers with the respective patient number (Kruskal-Wallis (K-W) 
test).  
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Figure 4.4.9. DNA damage in patients and controls (all subjects n = 20, 10 each 
group) relating to smoking: active smoker (n = 8), ex-smoker (n = 3) and non-
smoker (n = 9) groups, after in vitro treatment with H2O2 (50 μg/ml) and 
supplementation with the flavonoid quercetin at different concentration levels. 
The  symbol followed by a number indicate individual outliers with the 
respective patient number (Kruskal-Wallis (K-W) test).  
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Figure 4.4.10. DNA damage in patients and controls (all subjects n = 20, 10 each 
group) relating to smoking: active smoker (n = 8), ex-smoker (n = 3) and non-
smoker (n = 9) groups, after in vitro treatment with IQ (50 μg/ml) and 
supplementation with the flavonoid epicatechin at different concentration levels. 
The  and  symbols followed by a number indicate individual outliers with the 
respective patient number (Kruskal-Wallis (K-W) test).  
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Figure 4.4.11. DNA damage in patients and controls (all subjects n = 20, 10 each 
group) relating to ethnicity: Caucasian (n = 12) and Asian (n = 8) groups, after in 
vitro treatment with H2O2 (50 μg/ml) and supplementation with the flavonoid 
quercetin at different concentration levels. The   symbol followed by a number 
indicate individual outliers with the respective patient number (Kruskal-Wallis 
(K-W) test).  
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Figure 4.4.12. DNA damage in patients and controls (all subjects n = 20, 10 each 
group) relating to ethnicity: Caucasian (n = 12) and Asian (n = 8) groups, after in 
vitro treatment with IQ (50 μg/ml) and supplementation with the flavonoid 
epicatechin at different concentration levels. The  and  symbols followed by a 
number indicate individual outliers with the respective patient number (Kruskal-
Wallis (K-W) test).  
 
b) Previous medication in the IBD group as a confounding factor 
As shown in figure 4.4.13 patients had been treated with a range of drugs for 
IBD, namely, azathioprine, mesalazine and pentasa, asacol, prednisolone, 
mercaptopurine alone or in combination prior to taking part in the study 
azathioprine & pentasa, azathioprine & mesalazine, mercaptopurine & 
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balsalazide (n = 6); asacol (n = 1); pentasa & prednisolone, prednisolone & 
mesalazine (n = 2);. Within the treatment groups, there appeared to be 
differences but they were not significant (figure 4.4.13). 
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Figure 4.4.13. 1. Azathioprine, mesalazine and pentasa, asacol, prednisolone, 
mercaptopurine alone or in combination prior to taking part in the study 
azathioprine & pentasa, azathioprine & mesalazine, mercaptopurine & 
balsalazide (n = 6) 
2. Asacol (n = 1) 
3.  pentasa & prednisolone, prednisolone & mesalazine (n = 2) 
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4.5. Discussion  
 
Crohn’s disease (CD) and Ulcerative colitis (UC), known as inflammatory 
bowel disease (IBD), are fairly common chronic inflammatory conditions of the 
gastrointestinal tract. Although the exact aetiology of IBD remains uncertain, 
dysfunctional immunoregulation of the gut is believed to be the main cause. 
Amongst the immunoregulatory factors, reactive oxygen species (ROS) are 
produced in abnormally high levels in IBD (Rezaie, 2007). An imbalance 
between antioxidants and ROS results in oxidative stress, leading to cellular 
damage (Rezaie, 2007). 
 
Food-derived heterocyclic amines (HCA) like IQ have been shown to be 
mutagenic in the Ames test inducing gene mutations and tumours in vivo 
(Adamson, 1995; Knize, 1995). Food mutagens may cause different
 
types of 
DNA damage from chromosomal
 
aberrations to subtle nucleotide alterations. 
Most food mutagens like HCA are able to form reactive DNA adducts by 
covalently
 
binding to nucleotides.
 
However, the effect of food mutagens in 
carcinogenesis can be
 
modified by heritable traits, namely, low-penetrant genes 
that
 
affect exposure of the mutagen to DNA through metabolic activation
 
and 
detoxification or other cellular responses to DNA damage. Also DNA damage 
seems to be
 
indirectly triggered by oxidative stress. When considering
 
the human 
diet, it should be recognized that food contains both,
 
mutagens and components 
that decrease cancer risk such as antioxidants (Goldman, 2003; Maeda, 1999). 
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The present study demonstrates that H2O2 and IQ are capable of inducing 
significant DNA damage as a result of oxidative stress (Figures 4.4.1, 4.4.2). 
There was a significant increase of DNA damage after treating lymphocytes 
with H2O2 and IQ, while a significant protective effect was found in the presence 
of the flavonoids quercetin and epicatechin (Figures 4.4.1 and 4.4.2). Flavonoids 
are known to have antioxidative properties in vivo (Rice-Evans, 2001) and 
modulate effects of food mutagens in vitro in human lymphocytes
 
and sperm 
(Anderson, 1998). Cooking fish and beef inevitably generate HCA especially at 
high temperatures (Schut, 1999), which are carcinogenic in mice,
 
rats and 
monkeys producing hepatic, intestinal and mammary
 
tumours (Schoeffner, 
2000). For instance, AIA (aminoimidazoazaarene), categorised as a subclass of 
HCA, can be found in the human diet (Schut, 1999; Haza, 2010; Najafzadeh, 
2009) and is only genotoxic after being
 
activated to electrophilic derivatives that 
form DNA adducts (Hatch, 2001). A variety of host drug-metabolising enzymes 
are able to activate and detoxify heterocyclic amines including enzymes like 
CYP1A2, N-acetyltransferase,
 
sulfotransferase, prolyl tRNA synthetase, 
phosphorylase and
 
COX isomers (Wolz, 2000; Huycke, 2004). In a case-control 
study, no associations
 
were found between CRC risk and polymorphisms within 
the genes of those enzymes (Sachse, 2002). This comprehensive analysis, 
however, failed to consider
 
commensal bacteria and their potential impact on 
HCA activation, an effect independent of the host genotype. The pro-carcinogen 
IQ
 
is predominantly produced through the pyrolysis of creatinine with sugars 
and becomes significantly mutagenic in the presence
 
of hepatic microsomes 
(Sugimura, 1983; Turesky, 2007). Anaerobic
 
colonic bacteria can convert IQ to 
2-amino-3-methyl-3H-imidazo[4,5-f]quinoline-7-one
 
(HOIQ), a direct-acting 
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mutagen (Bashir, 1987). Intestinal anaerobic bacteria like Eubacterium spp. and 
Clostridium spp.
 
specifically metabolise IQ to HOIQ along with yet undefined 
commensal
 
bacteria in mice, rats, and humans (Carman, 1988; Van Tassell, 1990; 
Rumney, 1993). These commensal
 
bacteria can strongly influence IQ-induced 
DNA damage in colonic
 
cells and also in hepatocytes as measured by the 
alkaline Comet assay (Knasmuller, 2001). DNA from axenic rats exhibited
 
significantly fewer alkaline-labile breaks than rats colonised
 
with conventional 
murine or human commensal bacteria. In contrast,
 
other intestinal commensal 
bacteria including Bifidobacterium longum
 
and lactobacilli appear to be 
antagonistic to the mutagenic effects
 
of IQ (Reddy, 1993; Knasmuller, 2001). 
Mechanisms underlying these observations are
 
unclear but may involve 
inactivation of IQ or direct binding
 
of IQ to bacteria (Rumney, 1993). 
Modulating effects of two flavonoids, quercetin and rutin, on the mutagenic 
anticancer drug mitomycin C have been found using the Comet assay with 
human lymphocytes (Undeger, 2004). Quercetin significantly reduced DNA 
strand breakage induced by mitomycin C displaying protective effects 
supporting other findings where flavonoids modulated effects of food mutagens 
(Anderson, 1998). Flavonoids have a long history of use in preventing capillary 
fragility and bruising, but also some of the research has focused on their 
anticancer benefits (de Whalley, 1990; Ren, 2003; Mochizuki, 2010). Green tea 
and, to a lesser extent, black tea are a rich source of still another group of 
flavonoids called catechins. These catechins - including the closely related 
epigallocatechin-3 gallate (EGCG), epigallocatechin (EGC) and epicatechin-3 
gallate (ECG) - form about 30 percent of the dry weight of tea leaves (de 
Whalley, 1990). It was found that drinking green tea could prevent cancer 
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(Jankun, 1997; Romier, 2009): EGCG in green tea has been identified as a 
potent inhibitor of urokinase, an enzyme used by cancer cells to invade and 
metastasise. A single cup of green tea contains enough EGCG to temporarily 
inhibit urokinase activity - and is safer than synthetic drugs that block urokinase 
activity. 
 
 
 
In conclusion, flavonoids significantly reduce oxidative stress in vitro in 
lymphocytes of IBD patients and more so in CD than UC patients as well as 
healthy individuals. Thus, a diet containing flavonoids could be very effective in 
reducing baseline and exogenously induced oxidative DNA damage of IBD 
patients.  
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5. Introduction 
 
In this chapter lymphocytes from patients with cancerous and pre-cancerous 
states were exposed to UVA and compared with lymphocytes after UVA 
exposure in healthy control individuals. 
 
5.1.1. UVA exposure 
 
UVA (315-400 nm) (Figures 5.1.1, 5.1.2) radiation can have significant effects 
on the cells. DNA is certainly one of the key targets for UV-induced damage in a 
variety of organisms ranging from bacteria to humans. The most prevalent DNA 
lesions induced by UVB and UVA are the cyclobutane pyrimidine dimers (CPDs) 
and the pyrimidine (6-4) pyrimidine photoproducts ((6-4) PPs). However, cells 
have developed a number of repair or tolerance mechanisms to counteract the 
DNA damage caused by UV or any other stressors (Sinha, 2002). 
 
  
Figure 5.1.1.Electromagnetic spectrum 1 
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Figure 5.1.2.Electromagnetic spectrum 2 
 
 Intracellular and extracellular oxidative stress initiated by reactive oxygen 
species (ROS) advances skin aging, which is characterized by wrinkles and 
atypical pigmentation. Because UV enhances ROS generation in cells, skin aging 
is usually discussed in relation to UV exposure (Masaki, 2010). 
Constitutive skin pigmentation dramatically affects the incidence of skin cancer, 
and the photoprotective function of melanin in skin is highly significant. The rate 
of malignant melanoma even squamous and basal cell carcinomas is higher in 
Caucasians than in African Americans. Cyclobutanate-pyrimidine dimmers 
(CPDs) and 6-4 photoproducts (6-4 PPs) are the products resulting from UV 
damage on DNA lesions which accelerates production in Caucasians because of 
the lack of melanin (Tadokoro, 2003). 
In a study by Kimura, Lee et al 2010, UV-induced cancer cell death was wave-
length and dose dependent, as well as cell-line dependent. After UVA exposure, 
most cells were viable even when the UV dose was increased up to 200 J/m. 
With UVB irradiation, cell death was observed with irradiation at 50 J/m 
(Kimura, Lee et al. 2010).  
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 The repair of damaged DNA takes place in G1/G2 phases of cell cycle, the wild 
type p53 plays a major role in the induction of transient G1 and/or G2 arrests, 
and the expression of gadd45 (growth arrest and DNA damage gene) and 
gadd153 is also associated with the cell cycle arrest and DNA damage. Transient 
cell cycle arrest and the expression of p53, gadd45 and gadd153 in normal 
human oral keratinocytes, HPV-immortalized oral keratinocytes, and an oral 
cancer cell line expressing mutant p53 were investigated after exposing cells to 
UV light. The level of gadd45 transcripts was enhanced in all tested cells, but 
normal cells demonstrated a higher increase in the level of gadd45 after UV-
exposure compared to other tested cells. The level of gadd153 gene transcripts 
was only increased in normal oral keratinocytes after UV-irradiation. These data 
indicate that UV-induced transient G1 arrest in normal oral keratinocytes may be 
associated with both enhanced levels of intranuclear wild type p53 (Gujuluva, 
1994). 
 Protein damage is incredible in the process of inactivation by sunlight. Protein 
damage in UVA-irradiated Escherichia coli cells has been evaluated by an 
immunoblot method for carbonylated proteins and an aggregation assay based on 
semi-quantitative proteomics. A wide spectrum of structural and enzymatic 
proteins within the cell is affected by carbonylation and aggregation. Vital 
cellular functions like the transcription and translation apparatus, transport 
systems, amino acid synthesis and degradation, respiration, ATP synthesis, 
glycolysis, the TCA cycle, chaperone functions and catalase are targeted by 
UVA irradiation. The protein damage pattern caused by SODIS (Summary Solar 
disinfection) strongly resembles the pattern caused by reactive oxygen stress. 
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Hence, sunlight probably accelerates cellular senescence and leads to the 
inactivation and finally death of UVA-irradiated cells (Bosshard, 2010). 
 
 
 
5.1.2. Oxidative stress and cancers 
 
Oxidative DNA damage is an unavoidable consequence of cellular
 
metabolism 
(Cooke, 2003) and it affects constantly the carcinoma cells in vivo and in vitro 
(Brown, 2001) (Figure 5.1.3).  
 
 
Figure 5.1.3. Oxidative stress and environment 
 
Oxidative stress results from cellular metabolism and interaction with cells of 
exogenous sources such as carcinogenic compounds, redox-cycling drugs and 
ionizing radiation (Cooke, 2003). Superoxide and a significant amount of 
reactive oxygen species (ROS) are generated during mitochondrial oxidative 
phosphorylation (Yakes, 1997). There are some assays showing that mtDNA is a 
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critical cellular target for ROS and cancer and chronic inflammatory diseases 
generate
 
ROS as part of the pathophysiological mechanism (Moller, 2002 ; 
Yakes, 1997). Cells have
 
developed a complex network of defence barriers to 
neutralize
 
the generation of ROS and protect against the oxidation of 
macromolecules
 
by scavenging ROS (Moller, 2002). Ultraviolet A (UVA) and 
hydrogen peroxide (H2O2) both generate reactive oxygen species (ROS) making 
them relevant in the study of skin cell responses to oxidative stresses (Hazane-
Puch, 2010). This effect may be the result of a two-faced character of ROS acts 
as secondary messengers in intracellular signalling cascades, which induce and 
maintain the oncogenic phenotype of cancer cells and also induce cellular 
senescence and apoptosis (Valko, 2006). A novel feature of our study is that we 
used peripheral lymphocytes as  target cells instead of cancer cells directly, since 
the genome damage to the lymphocytes of peripheral blood has been widely used 
as a biomarker of genotoxic environmental factors, and long-term studies have 
demonstrated its validity and high clinical productivity (Hagmar, 2004) (Figure 
5.1.4). Possibly both oxidative stress and antigen-mediated preferential cell death 
of antigen-experienced memory cytolytic T lymphocytes (CTLs) may be a major 
contributor to tumour-induced immune dysfunction and phagocyte-derived ROS 
have been ascribed a suppressive role in immunoregulation by
 
inducing 
dysfunction and apoptotic cell death in lymphocytes (Thoren, 2007).  
 
 
 
 
The oxygen radicals have been
 
projected to contribute to the dysfunction of 
cytotoxic lymphocytes
 
characteristic of malignant disorders and chronic 
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infections
 
(Hellstrand, 2003). The oxygen radical-induced inactivation
 
of 
lymphocytes may constitute a significant mechanism of immunosuppression and 
the role of cytotoxic lymphocytes in malignant diseases (Gelderman, 2006).
 
Although oxygen
 
radical-induced inhibition of lymphocyte function thus may 
contribute
 
to protection against autoimmunity, a reverse situation appears
 
the
 
approach in malignant diseases. Thus, oxygen radicals,
 
formed by phagocytic 
cells at the site of malignant expansion,
 
are believed to significantly contribute to 
the characteristic
 
state of energy (effectively freezing T cell responses pending a 
"second signal" from the antigen-presenting cell) of cytotoxic lymphocytes in, 
e.g., colorectal
 
cancer, malignant melanoma, renal cell carcinoma, and certain 
hemopoietic cancers, in addition to chronic viral infections
 
such as HIV and 
hepatitis C (Samlowski, 2003; Hellstrand, 2003). In the origin
 
of several diseases 
as well as cancer, oxidative damage
 
to the cellular macromolecules occurs 
(Chatterjee, 1989). Antioxidants are molecules which can safely interact with 
free radicals and terminate the chain reaction before vital molecules are damaged 
and there are several enzyme systems within the body that scavenge free radicals. 
The same as for other cancers, imbalance in the redox status of oral cancer 
patients may be due to enhanced lipid peroxidation and compromised antioxidant 
defences (Subapriya, 2003). The biomarkers of oxidative stress and inflammation 
can be produced and modulateed by an antioxidant micronutrient cocktail in 
humans (Hopkins, 2010). ROS are independent of TP-triggered (thymidine 
phosphorylase) signalling transduction and are associated with increased tumour 
invasion. Thus ROS may provide improved therapeutic results as well as a 
preventative effect on carcinogenesis of the colorectum (Inokuma, 2009).  
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Antioxidants are intimately involved in the prevention of cellular damage; the 
common pathway for cancer, aging, and a variety of diseases (Thompson, 2004). 
The modifications caused by ROS and RNS may result in gene mutation and 
membrane alterations, as it has been shown for the tumour suppressor gene p53 
(Pacher, 2007) and ceramide release (Grether-Beck, 2000), respectively, 
following UVA irradiation. A recent study showed the vulnerable cancer cells 
can be more sensitive to UVA radiation than normal skin cells because they are 
unable to repair themselves as efficiently (Tang, 2010). 
 
 
 
 
5.1.3. Malignant melanoma and suspected melanoma  
As mentioned before cutaneous malignant melanoma, is the most lethal form of 
skin cancer, which has become an important public health issue because in the 
U.K. over 8,000 cases are currently diagnosed each year and the numbers are 
steadily rising. Worldwide, the number of new cases of melanoma is increasing 
faster than any other cancer and melanoma mortality is also rising (Vasquez-
Moctezuma, 2010). These figures make melanoma an important cancer for study. 
The majority of melanomas arise sporadically but in about 5% of cases there is a 
history of melanoma in two or more close relatives. Cases of familial cancer have 
been very informative in learning more about the genetics of sporadic cases in 
other cancers, e.g. colon cancer (Psaty, 2010). Two high-risk genes have been 
implicated in the development of malignant melanoma. Germ line mutations of 
the CDKN2A gene are found in < 25% of melanoma-prone families and there are 
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only seven families with mutations of the CDK4 gene reported to date. The 
CDKN2A locus encodes two gene products involved in cell growth regulation 
(Peric, 2008). It is identified germ line CDKN2A mutations in 31.3% of families; 
this figure rises to 50% in families with three or more first-degree relatives. By 
collaborating with international colleagues to demonstrate that the M53I 
mutation in the CDKN2A gene, which is present in a proportion of melanoma 
families' worldwide, appears to have arisen in the North of England, and it is 
clear that there remain two-thirds of melanoma families who must also have a 
gene abnormality (Lang, 2007). Exons and introns refer to specific nucleotide 
base sequences in the genetic code that are involved in producing proteins.  
 
 
 
 
Figure 5.1.4.Cancer and risk factors 
 
Exons are the DNA bases that are transcribed into mRNA and eventually code 
for amino acids in the proteins and transcription from exon 2 and 3 is shared by 
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p16 and p14, in different reading frames. P16 initiates within unique exon 1 and 
p14 also within exon 1, which is located approximately 20 kbp upstream of exon 
1. Melanocytes are producing melanin after UV irradiation as a defence 
mechanism. However, UV-induced damage is involved in melanoma initiation, 
depending on skin photo type. Melanocytes seem to be extremely susceptible to 
free radicals. Their main enzymatic antioxidants are superoxide dismutase and 
catalase (Baldea, 2009).  
 
As the MMR enzyme (DNA mismatch repair) hMSH2 displays a p53 target gene, 
is induced by UVB radiation and is involved in NER pathways, studies have now 
been initiated to elucidate the physiological and pathophysiological role of MMR 
in malignant melanoma and nonmelanoma skin cancer development (Rass, 2008). 
Also, it is considered that UVA and UVB are equally critical players in 
melanoma formation. Whereas UVA can indirectly damage DNA through the 
formation of reactive oxygen radicals, UVB can directly damage DNA causing 
the apoptosis of keratinocytes by forming the sunburn cells. Besides action 
through mutations in critical regulatory genes, UV radiation may promote cancer 
through indirect mechanisms, e.g. immunosuppression and dysregulation of 
growth factors. The carcinogenic process probably involves multiple sequential 
steps, some, but not all of which involve alterations in DNA structure (Situm, 
2007). 
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5.1.4. Colorectal cancer and polyposis coli 
 
Colorectal cancer is a major cause of morbidity and mortality among various 
types of cancer in the Western world (Yang, 1999). Sporadic disease, in which 
there is no family history, accounts for approximately 70 percent of all CRCs. It 
is most common over the age of 50, and dietary and environmental factors have 
been etiologically implicated. Age is a major risk factor for sporadic CRC. It is a 
rare diagnosis before the age of 40, the incidence begins to increase significantly 
between the ages of 40 and 50, and age-specific incidence rates increase in each 
succeeding decade thereafter (Neugut 1990). One of the most common diagnosed 
cancers in human is colorectal cancer (Ozdemirler Erata, 2005). Colorectal 
cancer is associated with oxidative stress and also Ihsp70 (inducible heat shock 
protein 70) expression is suppressed
 
under induced oxidative stress conditions in 
malignant tissues
 
of patients with colorectal cancer (Ozdemirler Erata, 2005; 
Chang, 2008). The most common sort of polyp is a metaplastic polyp which can 
be very similar in appearance to adenomatous polyps also it has the potential to 
become malignant. In addition, familial polyposis coli develops multiple 
adenomatous polyps bears a very high risk of colon cancer (Stigliano, 2008).  
Reactive oxygen and nitrogen
 
species created by inflammatory cells can interact 
with key
 
genes involved in carcinogenic pathways such as p53, DNA mismatch
 
repair genes, and even DNA base excision-repair genes although NF- B and 
cyclooxygenases may also contribute (Itzkowitz, 2004). The gene with mutations 
that result in familial adenomatous polyposis (FAP) has been identified as 
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adenomatous polyposis coli (APC). Similarly, mutations in several genes that 
normally function in DNA mismatch repair result in HNPCC. Colorectal cancer 
is the result of accumulated mutations in several additional oncogenes or tumour 
suppressor genes, and this information leads to the formulation of a genetic 
model for the disease. Recent studies have also identified a relatively prevalent 
polymorphism in the APC gene in Ashkenazi Jews that is associated with an 
increased risk for colorectal cancer. The risk factors for CRC are both 
environmental and inherited. These studies present a paradigm based on the APC 
mutation (APC I1307K) for the screening of cancer susceptibility genes in the 
population at large. Significant progress has been made in understanding the 
molecular mechanisms that lead to it (Yang, 1999). The connection between 
inflammation and tumourigenesis is well-established and in the last decade has 
received a great deal of supporting evidence from genetic, pharmacological, and 
epidemiological data. Inflammatory bowel disease is an important risk factor for 
the development of colon cancer. Inflammation is also likely to be involved with 
other forms of sporadic as well as heritable colon cancer (Terzic, 2010). One 
study has elucidated the role of distinct immune cells, cytokines, and other 
immune mediators in virtually all steps of colon tumorigenesis, including 
initiation, promotion, progression, and metastasis (Terzic, 2010). The "serrated 
neoplastic pathway" describes the progression of serrated polyps, including 
sessile serrated adenomas and traditional serrated adenomas, to colorectal cancer. 
In the past, all serrated polyps (Terzic, 2010) were classified simply as 
hyperplastic polyps and were considered to have no malignant potential. 
Reappraisal of this view was largely driven by increasing recognition of the 
malignant potential of hyperplastic polyposis (Terzic, 2010). The acquisition of 
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genomic instability is a crucial feature in tumour development and there are at 
least 3 distinct pathways in colorectal cancer pathogenesis: the chromosomal 
instability (CIN), microsatellite instability, and CpG island methylator phenotype 
pathways. Most cases of colorectal cancer arise through the CIN pathway, which 
is characterized by widespread imbalances in chromosome number (aneuploidy) 
and loss of heterozygosity (Pino, 2010). Between 2% to 5% of all colon cancers 
arise in the setting of well-defined inherited syndromes, including Lynch 
syndrome, familial adenomatous polyposis, MUTYH-associated polyposis, and 
certain hamartomatous polyposis conditions (Jasperson, 2010). In addition to the 
syndromes, up to one-third of colon cancers exhibit increased familial risk, likely 
related to inheritance. A number of less penetrant, but possibly more frequent 
susceptibility genes have been identified for this level of inheritance. 
Clarification of predisposing genes allows for accurate risk assessment and more 
precise screening approaches (Jasperson, 2010). 
 
In the present study peripheral blood lymphocytes from cancerous and 
precancerous states were exposed to UVA and compared with similarly exposed 
lymphocytes from healthy control individuals. They were examined with the 
micronucleus and Comet assays in order to determine if there was any 
differential sensitivity to exposure within the different groups.   
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5.2. Material and methods 
5.2.1. Blood samples 
Peripheral whole blood was collected by venepuncture from 80 (male and female) 
individuals (5 groups: MM, SM, and CRC, PC and healthy control individuals, 
20 individuals per group). Ages range from 20 to 78 years old for the patients’ 
groups and from 24 to 58 years old for the healthy control group. MM and SM 
patients have received treatment at the Dermatology Department of the St Luke’s 
Hospital in Bradford, UK. CRC and PC patients have been treated at the 
Colorectal Surgery Department of St. Luke’s Hospital and Bradford Royal 
Infirmary (BRI), Bradford, West Yorkshire, UK. Twenty healthy volunteers were 
recruited within the Division of Biomedical Sciences at the University of 
Bradford (West Yorkshire, UK). Ethical permission was obtained from both the 
BRI Local Ethics Committee (reference numbers 04/QI202/132 and 
04/Q1202/15) and the University of Bradford’s sub-committee of Research 
Ethics involving Human Subjects (reference number 0405/8). 
 
5.2.2. Questionnaire for patients and controls 
A questionnaire was administered to each donor immediately after taking the 
blood sample. The completed questionnaire for the patient and control groups 
provided essential information about lifestyle, confounding factors and medical 
treatment or any other drug intake. (The sample of questionnaire is in the 
appendix1) 
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5.2.3. UVA source 
For UVA exposure, a table-top lamp housing two 15W PUVA tubes (Waldmann, 
Villingen-Schwenningen, Germany; bought from Athrodax Healthcare 
International Ltd, UK) was used. The spectrum of the PUVA tube ranged from 
320-410 nm with a maximum at 351 nm. The lamp was positioned 15 cm above 
the cell layer. For the micronucleus assay, the cells were irradiated in suspension 
in Corning 25 cm
2
 plastic culture flasks (VWR, UK), placed horizontally on the 
bench under the UV lamp. For the Comet assay, cells were exposed embedded in 
0.5% agarose on slides. 
 
5.2.4. The cytokinesis block micronucleus (CBMN) assay  
The materials and methods used in this study have been described in section 2.2. 
 
 
 
Photograph 5.2.1.Two BiMNis in binucleated cell in SM patient 
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Photograph 5.2.2. A BiBud in polyposis coli patient 
 
5.2.5. The alkaline Comet assay 
Isolated lymphocytes were isolated from whole blood of all patients and healthy 
individuals using Lymphoprep according to the manufacturer’s protocol (Axis 
Shield, Norway). Lymphocytes were treated with UVA for 15 minutes at 37 ºC at 
a mean sample surface intensity of 1.53  0.01 mWcm
-2
. Untreated lymphocytes 
served as a negative control. 20 patients of each SM, MM; and 20 patients of 
each PC, CRC; and 20 control individuals were used for the investigation.  
For each replicate slide, 50 cells were scored (100 cells in total from every 
sample). The % Tail DNA and Olive tail moment, a measure of tail moment 
length and the fraction of DNA in the Comet tail, was used to assess DNA 
damage (Tice, 2000).  
 
 179 
5.3. Results 
 
5.3.1. Micronucleus assay 
5.3.1.1. Healthy control individual group (HCI) 
After UVA treatment, lymphocytes of healthy individuals showed a statistically 
significant reduction in CBPI from 1.84 to 1.62 for UVA (p < 0.001) and to 1.67 
for MMC (p < 0.01) due to a significant decrease in binucleated cells (BiNC) as 
seen in Table 5.3.1. Additionally, UVA treatment significantly induced 
micronuclei in cytokinesis-blocked lymphocytes almost to the levels of the 
positive control MMC. The number of binucleated cells containing MN 
increased 2.8-fold (BiMN; p < 0.001) (Figure 5.3.1), but also the number of 
mononucleated cells with MN increased a significant 4-fold (MonoMN; p < 
0.01). However, there were no statistically significant differences in the number 
of nucleoplasmic bridges and nuclear buds (BiNPB and BiBud) found in BiNC 
(Table 5.3.1). 
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 Treatment CBPI %BiNC  BiMN BiNPBs BiBuds  MonoMN 
Healthy control 
Untreated 1.84 ± 0.08 56.03 ± 5.46  9.86 ± 2.64 0.00 ± 0.00 0.93 ± 0.97  2.71 ± 0.97 
UVA 1.62 ± 0.04 *** 41.80 ± 3.84 ***  27.50 ± 1.02 ***  0.60 ± 1.05 0.86 ± 0.67  10.79 ± 5.47 ** 
 MMC 1.67 ± 0.02 
** 47.60 ± 3.26 **  32.71 ± 3.54 ** 0.14 ± 0.87 1.43 ± 0.98*  12.00 ± 6.89 ** 
SM patients Untreated 1.61 ± 0.02 
§§ 49.70 ± 2.03 §§  20.00 ± 3.40 §§ 0.00 ± 0.00 0.00 ± 0.00  2.00 ± 1.76 
 UVA 1.47 ± 0.03 
‡‡ ¥ 37.90 ± 1.42 ‡‡  23.00 ± 1.57  0.00 ± 0.00 0.00 ± 0.00  7.00 ± 5.42 ‡ 
 MMC 1.36 ± 0.02 
‡‡‡ ¥¥ 30.30 ± 3.45 ‡‡‡ ¥  44.00 ± 2.46 ‡‡ 0.00 ± 0.00 4.00 ± 1.56 **‡‡  2.50 ± 0.42 
MM patients Untreated 1.73 ± 0.04 
§ 52.30 ± 3.75 §§  22.00 ± 1.89 §§§ 0.20 ± 1.42 4.20 ± 0.87 §  4.20 ± 3.64 §§ 
 UVA 1.52 ± 0.03 
‡‡ 46.50 ± 1.78 ‡‡  40.67 ± 2.16 ‡‡ ¥ 0.20 ± 0.78 6.40 ± 1.35* ‡  6.444 ± 2.63 
 MMC 1.67 ± 0.03 
‡ 49.70 ± 2.34 ‡  45.89 ± 2.85 ‡‡‡ ¥ 0.40 ± 0.93 6.50 ± 1.12 *‡  10.50 ± 4.85 ‡ 
PC patients Untreated 1.63 ± 0.06 
§§ 43.43 ± 4.46 §§§  13.41 ± 4.25 § 0.30 ± 1.23 1.60 ± 1.33 §  4.80 ± 2.67 § 
 UVA 1.38 ± 0.03 
‡‡‡ ¥¥ 31.13 ± 3.02 ‡‡‡ ¥  33.17 ± 3.93 ‡ 0.30 ± 0.75 4.00 ± 2.02** ‡‡  16.50 ± 11.33 ‡‡ 
 MMC 1.45 ± 0.03 
‡‡ ¥¥ 37.35 ± 2.87 ‡‡  33.08 ± 3.27 ‡ 0.17 ± 1.14 0.17 ± 0.56***  15.00 ± 6.89 ‡ 
CRC patients Untreated 1.61 ± 0.04 
§§ 42.88 ± 2.56 §§§  23.89 ± 1.66 §§§ 0.20 ± 0.00 2.50 ± 1.79 §§  3.60 ± 2.63 § 
 UVA 1.31 ± 0.03 ‡‡‡ ¥¥ 26.04 ± 1.65 ‡‡‡ ¥  34.40 ± 2.43 ‡ 0.00 ± 0.00 1.60 ± 1.34* ‡  22.60 ± 12.43 ‡‡‡ 
 MMC 1.51 ± 0.02 
‡ ¥ 30.30 ± 1.73 ‡‡ ¥  51.00 ± 1.45 ‡‡‡ ¥¥ 0.00 ± 0.00 0.20 ± 0.12***  21.40 ± 14.63 ‡‡ 
 
Table 5.3.1. The effect of UVA treatment on peripheral blood lymphocytes from suspected melanoma (SM), malignant melanoma (MM), polyposis coli (PC) and colorectal 
cancer (CRC) patients compared to healthy control individuals. 
*, ‡, §, ¥ - p < 0.05, , ‡‡, §§, ¥¥ - p < 0.01, , ‡‡‡, §§§, ¥¥¥ - p < 0.001;  
* indicates the level of statistical significance when comparing lymphocytes from healthy control  individuals after treatment with UVA and MMC to untreated lymphocytes; 
‡ indicates the level of statistical significance when comparing lymphocytes from patients after treatment with UVA and MMC to untreated lymphocytes; 
§ shows the level of statistical significance when comparing untreated lymphocytes from patients to healthy control individuals;  
¥ Shows the level of statistical significance when comparing treated lymphocytes from patients to treated healthy control individuals; 
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5.3.1.2. Suspected melanoma (SM) and malignant melanoma (MM) patients 
5.3.1.2.1. Groups 
For both groups, the mitotic index CBPI was significantly decreased from 1.61 (SM 
group) and 1.73 (MM group) to 1.47 and 1.52, respectively, after UVA treatment 
(both p < 0.01) and to 1.36 (p < 0.001) and 1.67 (p < 0.05), respectively, after MMC 
treatment (Table 5.3.1). Similarly, this was also observed for the percentage of BiNC 
in 1000 scored cells (mono-, bi- and, multinucleated). UVA treatment also induced 
cytogenetic damage significantly increasing the frequency of BiNC carrying MN. The 
significant increase of 1.1-fold (p < 0.05) for the SM group and 1.9-fold (p < 0.01) for 
the MM-group did not reach the increase in damage afflicted by the positive control 
compound MMC of more than 2-fold (p < 0.05 and p < 0.001, respectively) (Table 
5.3.1). For SM patients the frequency of MonoMN significantly increased by 3.5-fold 
(p < 0.05). This was not seen for lymphocytes from MM patients after UVA treatment. 
MMC treatment resulted only in a significant increase in MonoMN in the MM group 
(2.5-fold, p < 0.05). Although there was no statistically significant increase in 
observed BiNPB, the nuclear buds observed in BiNC increased significantly. For the 
SM group, while the UVA treatment did not induce any BiBud, MMC treatment did 
(4 in 1000 BiNC, p < 0.01). For the MM group, UVA as well as MMC treatment 
resulted in significant increases in frequencies of BiBud from 4 per 1000 BiNC to 
around 6.5 per 1000 BiNC (p < 0.05). 
When both groups were compared to the group of healthy control individuals (Table 
5.3.1, Figure 5.3.1), untreated lymphocytes from suspected melanoma and the 
malignant melanoma patients showed significantly lower CBPI frequencies, from 
1.84 to 1.61 (p < 0.01; SM group) and to 1.73 (p < 0.05; MM group), which can also 
be seen in the reduction of the percentage of BiNC. Additionally, the basic 
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cytogenetic damage (induced BiMN) was significantly increased in untreated 
lymphocytes from SM and MM patients by 2-fold (p < 0.01) and 2.2-fold (p < 0.001), 
respectively (Table 5.3.1, Figure 5.3.1). Neither frequencies of BiNPB, BiBud and 
MonoMN were significantly increased in the SM group; however, BiBud and 
MonoMN frequencies were significantly increased in the MM group by 4.5-fold (p < 
0.05) and 1.5-fold (p < 0.01), respectively. 
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Figure 5.3.1: The number of binucleated micronuclei (MNBN) in peripheral lymphocytes from MM, 
SM and CRC, polyposis compared to HCI group before and after treatment with UVA or mitomycin C 
in vitro using the MN assay.  
*, ‡, §, ¥ - p < 0.05, , ‡‡, §§, ¥¥ - p < 0.01, , ‡‡‡, §§§, ¥¥¥ - p < 0.001;  
* indicates the level of statistical significance when comparing lymphocytes from healthy individuals 
after treatment with UVA and MMC to untreated lymphocytes; 
‡ indicates the level of statistical significance when comparing lymphocytes from patients after 
treatment with UVA and MMC to untreated lymphocytes; 
§ shows the level of statistical significance when comparing untreated lymphocytes from patients to 
healthy controls;  
¥ Shows the level of statistical significance when comparing treated lymphocytes from patients to 
treated healthy controls; 
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5.3.1.3. Polyposis coli (PC) and colorectal cancer (CRC) patients groups 
 
For both groups, the mitotic index CBPI was significantly decreased from 1.63 (PC 
group) and 1.61 (CRC group) to 1.38 and 1.31, respectively, after UVA treatment 
(both p < 0.001) and to 1.45 (p < 0.01) and 1.51 (p < 0.05), respectively, after MMC 
treatment (Table 5.3.1). Similarly, this was also observed for the percentage of BiNC 
in 1000 scored cells (mono-, bi- and, multinucleated). Treatment with UVA also 
generated cytogenetic damage significantly increasing the frequency of BiNC 
carrying MN by 2.5-fold for the PC group and 1.4-fold for the CRC-group (both p < 
0.05). The significant increase in damage shown by MMC was 2.5-fold (p < 0.05) for 
the PC group and 2.1-fold (p < 0.001) for the CRC group (Table 5.3.1). Additionally, 
the frequencies of MonoMN significantly increased in both groups after UVA 
treatment by 3.4-fold (p < 0.01; PC group) and 6.3-fold (p < 0.001; CRC group), 
respectively, being in the same range as after the MMC treatment. There was no 
statistically significant increase in observed BiNPB. Nuclear buds found in BiNC 
after UVA treatment significantly increased for the PC group (from 1.6 to 4 per 1000 
BiNC; p < 0.01) and interestingly significantly decreased for the CRC group (from 
2.5 to 1.6 per 1000 BiNC; p < 0.05). After MMC treatment the frequency of BiBud 
significantly decreased for both groups.  
When both groups were compared to the group of healthy individuals (Table 5.3.1, 
Figure 5.3.1), untreated lymphocytes from polyposis coli and colorectal cancer 
showed significantly lower CBPI frequencies, from 1.84 to 1.63 (p < 0.01; PC group) 
and to 1.61 (p < 0.01; CRC group), which can also be seen in the reduction of the 
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percentage of BiNC. Additionally, the basic cytogenetic damage (induced BiMN) was 
significantly increased in untreated lymphocytes from PC and CRC patients by 1.4-
fold (p < 0.05) and 2.4-fold (p < 0.001), respectively (Table 5.3.1, Figure 5.3.1). 
Frequencies of BiNPB did not show any differences to those of the healthy individual 
group. However, BiBud and MonoMN were significantly increased in both groups by 
1.7-fold (p < 0.05) and 2.7-fold (p < 0.01), respectively, for the PC group and by 1.8-
fold (p < 0.05) and 1.3-fold (p < 0.01), respectively, for the CRC group. 
 
 
5.3.2. Comet assay 
5.3.2.1. Suspected melanoma and malignant melanoma patients groups 
UVA treatment of lymphocytes from patients with SM and MM showed significantly 
increased DNA damage, 1.9-fold and 2.3-fold (both p < 0.001), respectively, when 
compared to untreated lymphocytes (Figure 5.3.2). In addition, before treatment with 
UVA, the lymphocytes from SM and MM patients compared to HC there is a 
significant increase of DNA damage , 1.3-fold (both p < 0.05) (Figure 5.3.2). In 
addition, we detect significant differences DNA damage in lymphocytes from SM and 
MM after treatment with UVA in contrast to HC (P < 0.001).  
DNA damage within SM and MM compared to HCI group after in vitro treatment 
with PUVA using the Comet assay.  
*
, 
§, 
- p < 0.05, , 
§§
, 
 
- p < 0.01, , 
§§§
,  - p < 0.001;  
*
 indicates the level of statistical significance when comparing lymphocytes from 
healthy individuals after treatment with UVA and MMC to untreated lymphocytes; 
§
 shows the level of statistical significance when comparing untreated lymphocytes 
from patients to healthy controls;  
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Figure 5.3.2.DNA damage within SM and MM compared to HC group after in vitro treatment with 
UVA using the Comet assay.  
*, §, - p < 0.05, , §§,  - p < 0.01, , §§§,  - p < 0.001;  
* indicates the level of statistical significance when comparing lymphocytes from healthy individuals 
after treatment with UVA and MMC to untreated lymphocytes; 
§ shows the level of statistical significance when comparing untreated lymphocytes from patients to 
healthy controls;  
 
5.3.2.2. Polyposis coli and colorectal cancer patients groups 
UVA treatment significantly induced DNA damage (p < 0.001) in lymphocytes from 
all three groups (healthy individuals, PC and CRC). The measured OTM (Olive tail 
moment) increase were 3.2-fold for the PC group, 3-fold for the CRC group and 3.3-
fold for the healthy individual group. The general DNA damage in lymphocytes from 
CRC patients before UVA treatment was highest followed by PC patients and healthy 
control individuals, after treatment with UVA (Figure 5.3.3). After inducing the DNA 
damage to lymphocytes from CP and CRC patients compared to HCI the OTM of the 
patients groups increased significantly 1.38- fold for PC and 1.48-fold for CRC (p < 
0.05) (Figure 5.3.3). Additionally, the lymphocytes of the patients groups (PC and 
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CRC) before treatment with UVA by comparing to HC showed  increased 1.43-fold 
for PC and 1.6- fold for CRC (P < 0.05) (Figure 5.3.3). 
 
 
 
Figure 5.3.3. DNA damage within PC and CRC compared to HC group after in vitro treatment with 
UVA using the Comet assay. 
 *, ‡, § - p < 0.05, , ‡‡, §§- p < 0.01, , ‡‡‡, §§§ - p < 0.001;  
 * indicates the level of statistical significance when comparing lymphocytes from healthy individuals 
after treatment with UVA and MMC to untreated lymphocytes; 
‡ indicates the level of statistical significance when comparing lymphocytes from patients after 
treatment with UVA and MMC to untreated lymphocytes; 
§ shows the level of statistical significance when comparing untreated lymphocytes from patients to 
healthy controls;  
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5.4. Discussion 
 
 
Different sensitivities of body cells to genotoxins can be determined in peripheral 
blood lymphocytes. These cells are ideal to be used as surrogates for all other body 
cells even DNA is basically the same in all cells. Even though they have failed to be 
surrogates of cancer cells in the prediction repair activities of cancer cells {Herrera, 
2009 #89}, employing them for DNA damage induction studies they can be crucial to 
determine base line and induced DNA damage e.g. in the Comet assay. As peripheral 
lymphocytes are exposed to various environments inside the body by travelling in the 
blood stream, they reflect a common denominator of endogenously and exogenously 
induced damage from chemical and physical genotoxic insults such as food mutagens 
or oxidative stress. We have previously shown that treatment with hydrogen peroxide 
and the food mutagen IQ (2-amino-3-methylimadazo[4,5-f]-quinoline) induced more 
DNA damage in lymphocytes from patients with IBD, a disease prone to high levels 
of ROS, than in those from healthy individuals (Najafzadeh, 2009). Irrespective of the 
underlying condition patients with IBD on the other hand have an increased risk of 
developing CRC (Itzkowitz, 2004).  
 
In this study we assessed in vitro the different sensitivities of peripheral lymphocytes 
from patients diagnosed with two very common types of cancers, MM and CRC, or 
with their pre-cancerous states, SM and PC. Our results showed that lymphocytes 
from selected pre-cancerous states (SM and PC) and cancers (MM and CRC) had 
significantly decreased CBPI values, hence a lower mitotic index, as well as a 
significantly increased frequency of induced micronuclei in binucleated cells, i.e. 
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genetic damage, when compared to healthy control individuals (Table 5.3.1, Figures 
5.3.1). This effect was confirmed by examining the lymphocytes from SM, MM and 
PC, CRC and treating them with UVA and compared to healthy controls individuals 
in vitro in the Comet assay (Figures 5.3.2 & 5.3.3).These findings have been recently 
supported as newly diagnosed cancer patients were found to have elevated levels of 
DNA damage in peripheral blood lymphocytes (Vodicka, 2010. Levels of reactive 
oxidative and reactive nitrogen species in relation to the antioxidant status are most 
likely to be one of the reasons for this observed damage as they can transiently or 
permanently
 
damage nucleic acids, lipids and proteins and therefore can increase 
cancer risk (Thompson, 2004 ;Chatterjee, 1989). 
 
To induce DNA damage in vitro in lymphocytes from our selected patient groups, 
UVA was used as a generic mutagen. Compared to a chemical genotoxin, the 
advantage of using UVA light was the exact setting of exposure time and strength of 
the genotoxic insult. UVA is part of the sunlight with its electromagnetic spectrum at 
sea level (290-5000 nm) not only including the visible (56%) and infrared (39%) part 
but also ultraviolet (UV) light (5%) (Gonzalez, 2008). Mostly UVA (320-400 nm) and 
to a lesser extent due to atmospheric absorption UVB (290-320 nm) reaches the 
earth’s surface, while the germicide UVC part is completely filtered off. The UVA/B 
light has been commonly characterised as an environmental human carcinogen being 
also responsible for erythema (sun-burn), tanning, photo-aging and immune-
suppression. However, artificial UV sources, mainly emitting UVA, can also be found 
in tanning studios and for the treatment of psoriasis (Matsumura, et al., 2004; 
Volkmar, 2010). Absorption of UVA in tissue results in the generation of reactive 
oxygen and nitrogen species and labile iron which can in turn damage other bio-
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molecules such as DNA (McMillan, 2008; Reelfs, 2004). The most frequent type of 
DNA damage after UV exposure are cyclobutane pyrimidine dimers (CPD) being 
mostly contributed by marginal amounts of UVB while UVA induced oxidative DNA 
(Woollons, 1999). 
 
For the DNA damage examined after in vitro UVA treatment, our results showed that 
peripheral lymphocytes from patients diagnosed with the pre-cancerous states and the 
associated cancer have a significantly higher sensitivity to the genotoxic insult when 
compared to healthy individuals (Table 5.3.1, Figures 5.3.1, 5.3.2 and 5.3.3). The 
mitotic index CBPI significantly dropped by up to 19% compared to 12% for the 
group of healthy individuals. Interestingly, the decline in CBPI was smaller for the 
groups of pre-cancerous states and the highest for the CRC group (9% SM vs. 12% 
MM, 15% PC vs. 19% CRC). For the PC/CRC groups the decline in CBPI was even 
lower than that for the positive control (MMC treatment). After inducing DNA 
damage by UVA in peripheral lymphocytes from SM, MM patients groups and 
healthy control individuals, no differences were detected between patient groups and 
the HCI group. In contrast the PC and CRC patient groups compared to the HI group 
a reasonable increase after treatment with UVA was shown  in the Comet assay (p < 
0.05) (Figures 5.3.2 & 5.3.3).   
 
Malignant melanoma is a life threatening type of skin cancer. It originates from UV 
induced DNA damage in specialised skin cells, the melanocytes. This initial damage 
causes mutations which can lead to melanoma. However, the mechanism underlying 
the role of UV light exposure from sunlight in the aetiology of cutaneous MM is 
unclear. In xeroderma pigmentosum, a disease with severe sensitivity to UV, due to a 
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defect in nucleotide excision repair, there is a high incidence of MM, suggesting that 
DNA repair capacity (DCR) plays a role in sunlight-induced MM (Wei, 2003). Also, 
DCR reduction is one of the risk factors for MM and may have a separate role in 
susceptibility to sunlight-induced MM among healthy people (Wei, 2003). The 
interplay between genetic factors and the ultraviolet (UV) spectrum of sunlight such 
as specific signal transduction pathways that regulate cell cycling, differentiation and 
apoptosis is one of the mechanisms of UV induced skin cancers. Another mechanism 
includes mutations in genes coding for proteins in the Hedgehog pathway and in the 
p53 gene (de Gruijl, 2001). 
 
For the induced genetic damage in our study, the induction of BiMN after UVA 
treatment was higher in lymphocytes from cancer and pre-cancerous state patients 
(1.85-fold, p < 0.01, for the MM group, 2.47-fold, p < 0.05, for the PC group and 
1.44-fold, p < 0.05, for the CRC group) when compared to the control group (1.34-
fold, p < 0.001). Only those from patients of the pre-cancerous SM group was lower 
(1.05-fold, p <0.05) but still significantly increased. When compared to the genotoxic 
impact of MMC, UVA treatment produced generally lower frequencies of induced 
micronuclei (Table 5.3.1). Especially for the PC/CRC group of patients the 
significantly increased induction of micronuclei in mononucleated cells was obvious 
(Table 5.3.1) reaching 6.3-fold (p < 0.001) in the CRC group after UVA induction. 
Diseases like cancer have been shown to cause cellular instability increasing 
chromosomal damage seen in an increase in induced micronuclei using the MN assay 
(Yildirim, 2006). The genomic damage to the lymphocytes of peripheral blood has 
been widely used as a biomarker of genotoxic environmental factors, and long-term 
studies have demonstrated its validity and high clinical productivity (Hagmar, 2004). 
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In our study peripheral blood lymphocytes were used as surrogate cells to characterise 
induced DNA damage after a genotoxic insult. Induced micronuclei, the change in the 
mitotic index and the change in DNA integrity as assessed by the Comet parameters, 
served as biomarkers for genotoxic damage. This study shows that peripheral 
lymphocytes from patients diagnosed with pre-cancerous states and with the 
associated cancer treated in vitro with UVA are expressing different sensitivities to a 
genotoxic insult when compared to a healthy control group. Thus, the damage 
afflicted by UVA was significantly higher in lymphocytes which originated from 
individuals with cancer or a pre-cancerous state. In conclusion, our findings suggest 
that cells not in close proximity to the cancer or the pre-cancerous lesions might carry 
higher intrinsic damage due for instance to increased oxidative stress and are therefore 
more sensitive to genotoxic insults. This feature of differential sensitivity of 
lymphocytes from healthy individuals and patients with cancers or pre cancerous 
states may be used as an important biomarker in the screening and diagnosis of pre 
cancerous states and cancers in the early stage. 
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6.1. General discussion 
 
A significant protective effect of the Chaga mushroom as an ethanolic extract against 
oxidative DNA damage has been demonstrated after oxidative stress has been induced 
in vitro by H2O2 in lymphocytes obtained from IBD patients and healthy donors. This 
protection seems to be based on the antioxidative action of the Chaga extract by 
inhibiting oxygen radicals and therefore protecting against DNA damage. 
Furthermore, significant differences in response to DNA damage were also shown 
between treated and untreated lymphocytes from Crohn’s disease and Ulcerative 
colitis. Lymphocytes from patients with Crohn’s disease had increased basic levels of 
DNA damage. Overall this study suggests that the Chaga mushroom extract may be a 
potent antioxidant. Therefore, it could be a possible therapeutic agent or an adjunct to 
treatment in patients or a useful supplement in healthy individuals to generally inhibit 
excessive oxidative stress (Najafzadeh, Reynolds et al. 2007). 
We report for the first time the protective in vitro effect of quercetin and epicatechin 
against oxidative stress in lymphocytes from IBD patients and healthy individuals 
(Figures. 4.4.1 and 4.4.2). We were able to show that untreated lymphocytes from 
IBD patients had significantly increased DNA damage when compared to healthy 
individuals (Najafzadeh, 2008). Flavonoids dramatically reduced the basic DNA 
damage in lymphocytes from IBD patients treated with H2O2 and IQ. In vitro 
treatment with H2O2 and IQ significantly induced DNA damage by oxidative stress in 
both groups. When co-treated with flavonoids, a significant protective effect was 
shown against free radical damage to the DNA generated by H2O2 or IQ. There was a 
very high level of damage in the patient group without any treatment because of their 
background inflammation and IBD therapeutic drugs which they had taken, but both 
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patients and controls showed a parallel and gradual reduction in DNA damage after 
treating with flavonoids (Figures 4.4.1 and 4.4.2).  
 
Also in the present investigation lymphocytes from CD patients in two series of 
studies groups  appeared to have a greater level of baseline DNA damage than those 
from UC patients when compared to the whole patient group (p < 0.001), suggesting 
that lymphocytes from CD patients are more exposed to oxidative stress than other 
IBD subgroups (Figures 3.4.2 and 4.4.2). It becomes obvious that an excessive 
production of ROS and radical nitrogen metabolites  occur during the inflammation of 
the intestine from IBD patients (Kruidenier, 2003). It seems that a misbalanced 
production of pro-inflammatory and anti-inflammatory cytokines is characteristic of 
IBD and severely affects the immune homeostasis in peripheral blood cells, even 
more in CD than in UC patients (Sventoraityte, 2008). However, all subgroups react 
in the same way towards exogenous oxidative stressors as well as towards the 
inhibition of oxidative stress by flavonoids.  
By considering the definition of inflammation as the body's natural reaction to 
invasion by an infectious agent, toxin or physical, chemical or traumatic damage, it is 
known that chronic inflammation and infection are major causes of cancer (Schetter, 
2010). 
In our final project we investigated the sensitivity of peripheral lymphocytes from 
two different types of pre cancerous state and cancer patients to the induced DNA 
damaging effect of UVA and compared then to lymphocytes from healthy control 
individuals in the Comet and micronucleus assays. The determination the affect on 
tumour cells can be carried out by measuring indirectly of the effect of chemicals or 
physical agents (radiation) on evaluating DNA damage in surrogate cells, such as 
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peripheral blood lymphocytes of cancer patients (Herrera, 2009).The understanding 
of the pathogenesis and progression of cancer requires the establishment of the 
altered genetic/metabolic factors that are essential to the development, growth, and 
proliferation of the malignant cells (Costello, 2006). Generally, our data showed 
clearly that the peripheral lymphocytes from suspected melanoma and malignant 
melanoma, polyposis coli and colorectal cancer patients are highly sensitive to UVA 
exposure compared to the healthy control individuals (HCI) group in the 
micronucleus and Comet assays (p < 0.001)  (Table 5.3.1, Figure 5.3.1). This would 
suggest that baseline frequencies of different diseases compared to controls could be 
an important biomarker in the diagnosis of pre-cancers and early stage cancers. Also 
peripheral lymphocytes are a useful surrogate for cancers and pre-cancerous states 
since blood is present in all organs and tissues and DNA is basically the same in all 
cells.  
 
 
6.2. Future work 
 
Further work needs to be undertaken to determine if the responses to the treatment 
with UVA seen in the present study can be replicated with other cancer and pre-
cancerous states in larger numbers compared to healthy control individuals.  
This would strengthen the conclusions.  
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Appendix1 
A sample of questionnaire 
 
INFLUENCES ON SUSCEPTIBILITY TO IN VITRO DNA DAMAGE BY ENVIRONMENTAL AGENTS ON 
LYMPHOCYTES FROM Inflammatory bowel disease and cancers PATIENTS AND CONTROL SUBJECTS 
 
HOSPITAL NUMBER   DATE OF SAMPLE  
     
AGE   FASTING  NON FASTING  
     
SEX (PLEASE TICK) M F  CONSENT    Y / N  
ETHNIC GROUP   INFORMATION SHEET Y / N  
 
 
 
 
 
DIET WESTERN ASIAN OMNIVORE VEGETARIAN VEGAN 
 
 
 
        RECREATIONAL DRUG USE Y/N   
  
        IF YES PLEASE LIST  
MEDICAL 
 
 
 
      COMPLICATIONS OF CANCER  
     (Primary Sclerosing Cholangitis)  
     DYSPLASIA ON COLONOSCOPY  
     OTHER MEDICAL CONDITIONS  
     (PLEASE LIST)  
    Family History of Cancer  and  
    Colorectal Cancer   
 
MOST RECENT MEASURED 
 
 RESULT DATE   RESULT DATE 
WEIGHT    FBC   
HEIGHT    CRP   
BMI    LFTs   
CREATININE       
 
   OCCUPATION  
      CURRENT SMOKER  Y/N PAST SMOKER Y/N HOW MANY/MUCH PER WEEK? 
      CIGARETTES   CIGARS   PIPE   
      ALCOHOL Y/N               UNITS PER WEEK  
    
      VITAMINS / ANTI-OXIDANTS  
      (PLEASE LIST)  
  
      PRESCRIBED DRUG USE  
     ( PLEASE LIST)  
  
  COLORECTAL or other CANCER CROHN'S, 
UC, IBD 
   NO OF YRS  
     EXTENT    SITE  HISTOLOGY   SURGERY  
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Appendix 2 
 
The list of publications 
 
 
1. Najafzadeh, M., P. D. Reynolds, et al. (2007). "Chaga mushroom extract 
inhibits oxidative DNA damage in lymphocytes of patients with inflammatory 
bowel disease." Biofactors 31(3-4): 191-200. 
 
2. Najafzadeh, M., P. D. Reynolds, et al. (2009). "Flavonoids inhibit the 
genotoxicity of hydrogen peroxide (H(2)O(2)) and of the food mutagen 2-
amino-3-methylimadazo[4,5-f]-quinoline (IQ) in lymphocytes from patients 
with inflammatory bowel disease (IBD)." Mutagenesis 24(5): 405-411. 
 
3. Najafzadeh, M, A. Baumgartner,  et al (2010). In vitro evaluation of different 
sensitivities of lymphocytes from patients diagnosed with cancer or pre-
cancerous state by using UVA as a generic mutagen and employing the 
micronuclei assay and the Comet assay. submitted  
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Appendix 3 
The list of groups and confounding factors for chapter  4 
 
Group IBD type Gender Class Age smoking Alcohol Ethnic IBD treatment
1 3 1 11 27 1 1 1 1
1 2 1 11 22 1 1 1 1
1 1 2 12 58 2 2 1 1
1 1 1 11 31 2 2 1 1
1 2 1 11 38 3 2 1 2
1 2 1 11 65 1 0 1 3
1 1 1 11 30 3 0 2 1
1 3 1 11 39 2 2 1 2
1 1 2 12 59 3 0 2 1
1 2 2 12 55 1 2 1 2
2 2 21 25 1 1 1
2 1 22 20 3 0 2
2 2 21 22 1 1 1
2 2 21 24 1 1 1
2 2 21 26 1 1 1
2 1 22 34 3 0 2
2 1 22 56 3 0 2
2 1 22 40 1 1 2
2 1 22 22 3 0 2
2 2 21 20 3 1 1
 
Group 1: Patient group, group 2: Control group 
IBD type: 1; UC, 2;CD, 3; Indeterminate 
Gender: 1: Male, 2: Female 
Smoking: 1; non smoker, 2; smoker, 3; exsmoker 
Alcohol: 0; tea total (no alcohol), 1; mild (under 5 U / week), 2; moderate 
Ethnic: 1; Caucasian, 2; Asian  
IBD treatment: 1. Azathioprine, mesalazine and pentasa, asacol, prednisolone, mercaptopurine alone or 
in combination prior to taking part in the study azathioprine & pentasa, azathioprine & mesalazine, 
mercaptopurine & balsalazide (n = 6) 
2. Asacol (n = 1) 
3.  pentasa & prednisolone, prednisolone & mesalazine (n = 2) 
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Appendix 4 
The list of groups and confounding factors for chapter  3 
Counter Group IBD type Gender Age Smoking Alcohol Ethnic IBD treatment 
1 1 3 2 49 1 1 1 3 
2 1 1 2 48 1 0 1 7 
3 1 2 1 42 3 0 1 1 
4 1 2 1 49 1 1 1 6 
5 1 3 1 39 2 2 1 2 
6 1 1 1 30 3 0 2 5 
7 1 1 2 18 3 0 2 3 
8 1 2 2 55 2 0 1 2 
9 1 2 2 32 1 1 1 3 
10 1 1 1 49 3 0 1 1 
11 1 1 1 31 3 1 1 5 
12 1 2 1 22 1 1 1 2 
13 1 2 1 38 3 0 1 2 
14 1 1 2 59 3 0 2 3 
15 1 3 1 27 2 1 1 4 
16 1 1 2 42 2 2 1 8 
17 1 1 1 51 3 1 1 5 
18 1 2 1 53 1 1 1 2 
19 1 2 2 28 3 0 1 2 
20 1 3 2 42 3 0 1 8 
21 2 
 
1 36 1 0 2 0 
22 2 
 
1 30 1 0 1 0 
23 2 
 
2 26 1 1 2 0 
24 2 
 
1 22 1 1 2 0 
25 2 
 
1 39 1 0 2 0 
26 2 
 
2 31 1 0 1 0 
27 2 
 
2 21 1 0 2 0 
28 2 
 
1 41 1 1 2 0 
29 2 
 
2 23 1 1 1 0 
30 2 
 
1 29 3 1 1 0 
31 2 
 
2 26 1 0 1 0 
32 2 
 
1 22 3 2 1 0 
33 2 
 
1 41 1 2 2 0 
34 2 
 
1 41 1 1 2 0 
35 2 
 
1 57 1 0 2 0 
36 2 
 
1 33 1 0 2 0 
37 2 
 
1 30 1 1 1 0 
38 2 
 
1 25 1 0 1 0 
39 2 
 
2 40 3 1 2 0 
40 2 
 
2 34 1 0 2 0 
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Group 1: Patient group, group 2: Control group 
IBD type: 1; UC, 2;CD, 3; Indeterminate 
Gender: 1: Male, 2: Female 
Smoking: 1; non smoker, 2; smoker, 3; exsmoker 
Alcohol: 0; tea total (no alcohol), 1; mild (under 5 U / week), 2; moderate 
Ethnic: 1; Caucasian, 2; Asian  
IBD treatment: 1. Azathioprine, mesalazine and pentasa, asacol, prednisolone, mercaptopurine alone or 
in combination prior to taking part in the study azathioprine & pentasa, azathioprine & mesalazine, 
mercaptopurine & balsalazide (n = 6) 
2. Asacol (n = 1) 
3.  pentasa & prednisolone, prednisolone & mesalazine (n = 2) 
 
